



Organisation of Pharmaceutical Producers of India

**Collaboration  
Creation**



**Conservation  
Communities**

PUTTING THE  
**COUNTRY  
FIRST.**

TAKING THE  
**COUNTRY  
FAR.**



**We were there**  
**We are there**  
**We will be there**  
**#BharatKeLiye**



Scan to know more

Map not to scale



## FOREWORD

**Anil Matai**

Director General, OPPI

Success stories are best built on sustainable solutions. And this is precisely the approach adopted by OPPI and its member companies in building a stronger, healthier India – *Bharat Ke Liye!*

Our aim has been unwavering, from our inception itself. Bringing the best in medicines to fulfil the country's unmet medical needs, while pushing the boundaries of the pharma industry. Thus, through the years, through innovative breakthroughs, our member companies have helped lessen the disease burden of the nation. Convincingly.

Walking shoulder to shoulder with the government now on its '*Bharat Ke Liye*' journey, they are even more keenly focused on investing in the research of new medicines

and treatment options. Creating a world class, robust, yet sustainable pharmaceutical industry that has the country standing tall.

Last year, their unparalleled advances in the field have taken this endeavour further. Indeed, 2023 has seen a quantum leap in treatment options, in the development and launch of newer, improved medicines, as well as multiple tie ups with both medical and educational institutions, NGOs and much more. All with the aim of ensuring sustainability and increasing accessibility.

This report enlists 23 of our member companies whose efforts have been exemplary. Who have set the bar higher - *Bharat Ke Liye*, and will continue to do so!

# INDEX

## OPPI ORDINARY MEMBERS

- 06** **Abbvie**  
AbbVie's CSR initiatives: Nurturing education, wellness and vision
- 12** **AstraZeneca**  
Reimagining the future of healthcare with the power of science
- 20** **Bayer**  
Health for all, Hunger for none
- 26** **Boehringer Ingelheim**  
Sustainable solutions across the spectrum
- 36** **Bristol Myers Squibb**  
Transforming patients' lives through science
- 42** **Lilly**  
Lilly India – Creating medicines to make lives better
- 46** **Ferring Pharmaceuticals**  
Ferring's FDG technology: A game-changer in convenience and effectiveness
- 48** **GSK**  
A century of commitment, a legacy of trust
- 52** **Merck**  
We help create, improve and prolong lives

- 56** **Novartis**  
Reimagining medicines and championing patient engagement
- 64** **Novo Nordisk**  
Driving change to defeat serious chronic diseases
- 68** **Otsuka**  
Quality. Trust. Wellbeing.
- 72** **P&G Health**  
Getting closer to our communities through 'SEHAT'
- 76** **Pfizer**  
In India, for India and the world
- 80** **Roche**  
Sustainable solutions for stronger communities
- 84** **Sanofi**  
Serving communities through Science
- 88** **Servier**  
Placing patients at the heart of our innovation
- 92** **Takeda**  
A promising partnership to promote healthcare innovation

## OPPI AFFILIATE MEMBERS

- 94** **ACG**  
Creating a better tomorrow for the community today
- 104** **DHL**  
Delivering with Care for Planet & People
- 108** **Indegene**  
Enabling healthcare organizations to be future-ready
- 112** **Parexel**  
Rewards, Recognitions and Resourcefulness
- 116** **Pharmapoint**  
Supply that's Safe, Secure & Sustainable

## AbbVie's CSR initiatives: Nurturing education, wellness and vision

Standing tall in the pharma world, AbbVie's steadfast mission has always been to deliver innovative medicines and solutions that address multiple health issues and enhance people's lives. Making us a renowned name in several therapeutic areas, such as immunology, oncology, neuroscience, eyecare, and women's health, amongst others; treating 75+ conditions in over 70+ countries. Equally committed to our social responsibility, AbbVie has crafted a transformative CSR program with profound impact fostering education, well-being, and vision among underprivileged communities.

### Our vision: Better vision and brighter futures!

AbbVie collaborated with Sightsavers India in presenting the RAAHI program, dedicated to promoting eye health among the vital trucking community. In 2023-2024, we joined hands with Sightsavers to establish 4 Vision Centers and 3 Exclusive Camp Locations, screening 29,000 truckers and dispensing 13,000 spectacles. Notably, 230 individuals were identified with cataract and other eye issues, showcasing our commitment to enhancing vision and empowering lives.

Recognizing glaucoma as the "silent thief of sight," AbbVie's Glaucoma Awareness Project in association with Sightsavers India strives to raise awareness and facilitate screenings about the disease. Offline awareness efforts, social media impressions, and targeted screenings in multiple locations have collectively made a significant impact, reaching over 1.5 lakh individuals offline and creating 1.5 crore impressions on social media. The screening and referral of 5700 individuals underscore AbbVie's dedication to illuminating paths to eye health.

We have also stepped forward to support the Christel House Character Education and Life Skills Program, emphasizing values for personal growth and citizenship. In 2023-2024, AbbVie's impactful sponsorship reached 35 Grade-10 students for STEM education and enabled 140 Grade-1 and Grade-2 students in pursuing their educational journeys.

AbbVie has partnered with the Mobility India project to address health and education disparities in underprivileged communities. In 2023-2024, this initiative positively impacted 437 individuals with disabilities, facilitating rehabilitation services, nutritional support, and knowledge on disability and early intervention. These efforts have played a pivotal role in enabling individuals to pursue education, secure livelihoods, and independently carry out daily activities.

AbbVie's CSR initiatives stand as a testament to our strong commitment towards creating positive, sustainable change in the lives of those in need, encompassing education, wellness, and vision.

### AbbVie in Partnership with Sightsavers India

- **Static Center Model:** Establishment of Vision Centers at locations with regular flow of truck drivers across national highway routes, such as Transport Nagar
- **Outreach Model:** Outreach camps are conducted in transport hubs, fleet sites, etc.
- Primary screening, refraction, eye health counseling and spectacle dispensing conducted at static centers & camps
- Eye health awareness created among the truckers by Community health worker and flyers distributed on eye health awareness to truck drivers
- 94% glasses are dispensed on the spot (Near vision glasses and R2C). 6% glasses for distance vision ordered through a data entry software, with delivery after 10 days
- Patients identified with other eye health problem referred to base hospital

### RAAHI- National Truckers Eye Health

**Project Goals :** To ensure road safety & enhance quality of life through enabling clear eye vision among truck drivers & allied workers.

**Project Period: Oct 22 - May 24**

#### 4 Vision Centers

Udaipur, Hyderabad, Jamshedpur, Mangalore

#### 3 Exclusive Camps

Dhar, Dhanbad and Jodhpur

#### Achievement YTD

29k Truckers Screened  
13K spectacles Dispensed  
230 Identified with Cataract & other eye issues





### Christel House India

The school dedicated to break cycle of poverty by providing education to children from households with income less than USD 32/month

Education is provided in English, enabled with technology, Health services, food and counselling.

#### Project Goals with support from AbbVie

1. STEM Education Sponsorship of impoverished students studying in Grade 10
2. Education Sponsorship for 70 impoverished students studying In Grade 1
3. Education Sponsorship for 70 impoverished students studying In Grade 2



## Mobility India

An organisation which facilitates disability inclusion, physical rehabilitation and assistive technology to build strong communities

### Project Goals

Support walk-ins at the center looking for assistive therapy and affordable devices (adults & children) made at the center, using innovative technologies

Supports caregivers & patients with adequate skills and self care for improving health

Education and training in Disability and Rehabilitation

Provide basic menstrual hygiene and health education and information on child rights and safety and menstrual hygiene to girls and women with disabilities



## Reimagining the future of healthcare with the power of science

AstraZeneca India takes pride in its unwavering commitment to revolutionize healthcare through the force of scientific breakthroughs. In the pursuit of delivering life-changing medicines and addressing global health challenges, we stand at the forefront of the healthcare industry, shaping the future with cutting-edge science.

Embracing the “Science Can We Can” mindset, our organization is driven by shared values that prioritize service to people, society, and the planet.

### The Power of Science: Achieving Exceptional Milestones in 2023

As a science-led biopharmaceutical company, AstraZeneca thrives on pushing the boundaries of science to deliver life-changing medicines. The year 2023 witnessed outstanding achievements, marked by notable regulatory approvals and submissions, including approvals for our medicines or life-cycle management indications, and advancements in our pipeline.

We introduced a diverse selection of innovative therapies aimed at addressing Chronic Obstructive Pulmonary Disease (COPD), Breast Cancer, and Neurofibromatosis 1 (NF1). Additionally, we are extending our reach by venturing into the Rare Diseases spectrum, addressing NF1, and marking a significant expansion of our portfolio.

Our commitment to improving health in India revolves around three key pillars: ensuring the availability and affordability of our medicines, supporting sustainable health systems and infrastructure, and promoting disease awareness and prevention.

### Putting Patients First & Doing the Right Thing

AstraZeneca’s values of ‘Putting Patients First & Doing the Right Thing’ have been pivotal to our growth story. Regulatory approvals across diverse therapy areas have expanded our reach, providing treatment options for patients many of whom had previously had no treatment options.

With unwavering commitment, we continue to introduce transformative medicines, especially for patients with limited or no treatment options. Our focus extends beyond medicines to developing a comprehensive roadmap for early diagnosis and holistic care in collaboration with stakeholders.

### Leveraging Advanced Technology for Healthcare Challenges

Recognizing the critical role of early diagnosis, AstraZeneca invests significantly in turning this vision into reality. Our India Innovation Hub is actively engaged in forging partnerships to ensure affordable and accessible healthcare. Flagship projects like HeartBeat, SEARCH, SAHAYOG, and others aim to disseminate accurate information on diseases and contribute to early detection efforts.

### Commitment to Society and Planet

Aligned with our value of ‘doing the right thing,’ AstraZeneca actively contributes to both society and the planet. The correlation between a healthy planet and healthy people guides our ambitious actions to expand healthcare access while mitigating climate change impact.

Through our Ambition Zero Carbon strategy, we pursue aggressive decarbonization targets and engage in global reforestation initiatives. Thus, we have expanded AZ Forest- our global reforestation and biodiversity initiative, to plant and maintain 200 million trees by 2030, to restore over 100,000 hectares of land, benefiting people, planet and the society.

In India, the project aims to support farmers restore 22,670 hectares of land, by planting and maintaining an estimated 64 million plants and trees in Meghalaya. We have collaborated with Earthbanc, Earthtree, Worldview Impact (India) and Hill Farmers Shiitake Mushroom Coop Society on the ‘Meghalaya Reforestation and Sustainable Livelihoods Project’ (Regeneration Meghalaya), a 30- year regenerative horticulture and agriculture project in northeast India.

Another initiative, our “Ganga Godavari Screening Programme” remains steadfast in identifying early cancer incidences among women in underserved communities, conducting over 130 preventative screening camps this year. Our Young Health Programme, focused on educating young people about health choices, has reached more than 5 lakh individuals through 21 health information centers across New Delhi and Karnataka.

As we reflect on our achievements and milestones, we are further strengthened in our dedication to transforming healthcare through ground- breaking science, commitment to patients, and responsibility towards society and the planet!

### Improving access to science with technology and strategic collaborations:

AstraZeneca’s commitment to enhancing healthcare access through technology and collaborations is evident through our many strategic initiatives.

### AI-based Lung Cancer Screening in Karnataka:

- A MoU was signed between the National Health Mission, Health & Family Welfare Services, Govt of Karnataka, and AstraZeneca Pharma India.
- The collaboration deploys Qure.ai's AI-based Lung Cancer screening technology, capable of screening a patient for 29 lung diseases in a single chest X-ray.
- Expected to benefit 1.4 lac patients across 19 district hospitals in the state.



### NGS Molecular Panel Testing at RGC&RC:

- A MoU was established between AstraZeneca India and the Rajiv Gandhi Cancer Institute and Research Center (RGC&RC).
- A Center of Excellence (CoE) will be set up at RGC&RC lab in Delhi, enhancing the availability of subsidized, high-quality, and validated Next-Generation Sequencing (NGS) molecular panel testing for individuals diagnosed with lung cancer in India.



### Centers of Excellence for Severe Asthma:

AstraZeneca launched five Centers of Excellence across India to standardize the management of severe asthma patients.

Notable facilities include a dedicated CoE at Bramha Kumaris Hospital in Mumbai and another at Manipal Hospital in Goa, aiming to redefine the diagnosis and treatment of severe asthma patients.



Mumbai



Goa



### Collaboration with Roche Diagnostics for Breast Cancer Diagnostics:

AstraZeneca India and Roche Diagnostics India signed a memorandum of understanding (MoU) to enhance diagnostics for breast cancer patients.

The collaboration focuses on streamlining HER2 diagnostics with advancements in the field.



### Commitment to Society and Planet Young Health Program (YHP)

Our Young Health Program, in partnership with John Hopkins School of Public Health and Plan International, focuses on improving health outcomes for vulnerable youth aged 10 to 24 globally, preventing common non-communicable diseases. Implemented for over a decade in New Delhi and Karnataka, the program, using peer educators, raises awareness about harmful behaviors. With support from local governments, including MoHFW and NCD Cell, we've impacted over 500,000 individuals, providing essential knowledge for a healthier future.



### Ganga Godavari Screening Programme

Our Ganga Godavari Screening Program prioritizes early cancer detection for women aged 30 to 60 in underserved areas. Launched in 2019, it collaborates with Indian Cancer Society and CAPED India, reaching over 8,500 patients in Tikri, Mathura, Nashik, and Patna through specialized screening camps and community education.





**Ambition Zero Carbon:**

At AstraZeneca we are committed to our Ambition Zero Carbon strategy, targeting a 98% reduction in GHG emissions from its operations and fleet (Scope 1 and 2) by 2026 and a 50% reduction in its entire value chain footprint (Scope 3) by 2030. With a goal of achieving a 90% absolute emissions reduction from a 2019 baseline, the company aims to be science-based net zero by 2045 at the latest. AstraZeneca's net-zero targets have been verified by the Science-Based Targets initiative, making it one of the first seven companies globally to achieve this recognition.

**AZ Forest:**

AZ Forest is AstraZeneca's commitment to plant and maintain over 200 million trees by 2030, in collaboration with experts and local communities. In Meghalaya, India, the goal is to plant and maintain around 64 million plants and trees, supporting farmers in restoring 22,670 hectares for biodiversity, soil conservation, and climate benefits. The project aligns with AstraZeneca's Ambition Zero Carbon strategy and contributes to both planetary and human health, with over 200,000 trees already planted and ongoing soil and water conservation efforts for additional tree planting in 2024.





## Health for all, Hunger for none

Bayer is a global enterprise with core competencies in the life science fields of healthcare and agriculture, whose products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Over the last 126+ years of our presence in India, the company has strived to establish itself as a trusted partner with significant contributions toward enhancing food security, increasing agricultural yield, providing innovative and accessible health care, and encouraging sustainable business practices.

### Committed to creating a healthier country

In India, the Pharmaceuticals Division operates as Bayer Zydus Pharma, a joint venture between Bayer and Zydus Cadila focused on the key disease areas of diabetes, heart health, renal care, women's health, ophthalmology and oncology. The Bayer Pharmaceuticals division includes the radiology business with a presence in devices and contrast agents.

India is one of the clinical trials footprint countries for Bayer globally, contributing to research-based data while also making innovative treatment options available to patients in India through phase 2-4 clinical trials. This, along with our Data Science and Analytics Centre, India contributes to Bayer's global R&D for pharmaceutical drug development, helping to launch new innovative therapies to address the unmet healthcare needs of patients.

### Rear view mirror - 2023

In 2023, Bayer maintained a successful trajectory on the back of 3 successful product launches that took place a year earlier. These novel therapies have continued to address unmet needs in the current treatment landscape for non-communicable diseases with high morbidity and mortality, and help patients achieve a better quality of life.

Kerendia (Finerenone) was the first non-steroidal selective mineralocorticoid receptor antagonist to slow down the progression of chronic kidney disease in patients with diabetes. The brand was in the top 5 launches in the India Pharmaceutical Market.

Verquvo (Vericiguat) is indicated to reduce the risk of cardiovascular deaths and repeated hospitalizations among patients with worsening heart failure. It was considered among the best cardiovascular launches globally and enjoyed a number 3 position in the market establishing Bayer as a leading company in the cardiovascular space.

Nubeqa (Darolutamide), for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone sensitive prostate cancer (mHSPC) was launched after showcasing very promising results. To offer accessibility and affordable pricing, while being able to reap the benefits of innovation, Bayer introduced some of these drugs by following a global tiered pricing approach. Kerendia and Verquvo we introduced through a country-specific pricing in accordance with per capita income and other healthcare metrics. In India, Kerendia was launched at 1/15th the price when compared to the US and Verquvo is priced at 1/20th of the price as compared to other countries.

### Taking India to the world and back

Globally, Bayer is committed to research and development and India is a formidable part of that story. Our Pharma R&D team established in Hyderabad, is a part of a global team, contributing to Clinical Data Operations (CDO), Data Science & Artificial Intelligence (DS&AI), Oncology Statistics & Data Management (OSDM) & Clinical Imaging & Application. The team actively contributes globally across clinical data science & analytics for global phase II/III studies and also contributes to the area of SAS programming, Medical Coding, Data management and Data Insight & Generations. They also support AI/ML projects like Cell Painting (assays analysis through digitalization/ exploration) for RED ONC research group and Radiomics Radiology, Biomarkers and Clinical datasets. Teams from Bayer India also actively contribute globally to Trial Feasibility and Analytics (TFA) and GCIS - General Clinical Imaging Services (Radiology R&D).

The Pharmacovigilance Regional center (PVRC) for Asia Pacific is currently located in India and many global pharmacovigilance activities including Global case processing, aggregate report writing, and IT support have been outsourced to TCS located in India.

In our endeavour to ensure the country's diverse population is better represented in innovation and to support faster introduction of innovative therapies, we have further increased the number of clinical trails being conducted here. In India, the company has around 18 projects across Phase II to IV, covering a range of potential therapeutic modalities and indications.

### Partnerships to promote access & affordability

With the goal of increasing access to healthcare for all, Bayer continues partnering with various organizations to co-create and cater to unmet needs in different disease areas.

The company has 7 patient support programs for various molecules to reduce the financial burden and make treatment options more affordable and accessible to patients while also improving adherence by providing counselling and other support services. The patient support program for Eylea (intravitreal aflibercept) has helped thousands of patients receive the benefits of the treatment by providing flexible and affordable payment solutions for patients in India to access aflibercept - an innovative treatment for macular degeneration and diabetic macular edema. **Visanne Values You** is a program for patients with endometriosis that aims to improve adherence to therapy and reduce the financial burden of the treatment in a self-pay dominant market. The program also offers counselling for women with endometriosis in various languages.

**EndoRun**, an initiative by Bayer and Patient Academy for Innovation and Research (PAIR), is a mass awareness initiative that brings together survivors, their families, healthcare providers, researchers, and advocates, to march for a shared cause around endometriosis. The goal is to spark a national conversation around the condition, and call for greater support and resources, for individuals and families affected by it. The first series of EndoRun was conducted in 2023 across Mumbai, Delhi, Pune and Kolkata with approximately 1000 participating in the events.



A glimpse from ENDORUN initiative:

We launched **#ReadyToSlowDown** with an aim to offer education on the management of Diabetes and associated cardiac and renal complications. The program backed by the Indian Society of Nephrology (ISN), offers support to physicians in the early detection and treatment of diabetic kidney disease. Aligned to Gol's focus on prevention and management of Chronic Kidney Diseases, the program also reached out to patients and their families through a social media campaign.

Bayer in India aims to meet the contraception needs of around 5 million women by 2030, which is in line with sustainable development goals set up by the United Nations. In collaboration with the Family Planning Association of India (FPAI), we plan to build sustainable models of care delivery for family planning for women in India. Bayer has also tied up with United Nations Family Planning Association (UNFPA), to support a program educating the youth on family planning through a chatbot and providing them options to consult with a healthcare provider.



The team from Bayer with FPAI

In keeping with the government's guidelines to reduce unnecessary hysterectomies, we have partnered with the Federation of Obstetric and Gynaecological Societies of India (FOGSI) to offer better options in family planning and safe contraception. The 'Preserve the Uterus' campaign aims to create awareness among women and educate healthcare practitioners about how a hysterectomy should be the last resort to manage uterine conditions, using alternate, non-invasive treatments instead. Since 2019, more than 7000 healthcare practitioners have been trained through over 80 sessions to educate and address the concern of unwarranted hysterectomies among women in India, and they in turn cascaded the sessions to post-graduate medical students.



The Preserve the Uterus (PTU) Campaign Launch

In 2023, Bayer collaborated with FOGSI to launch 'Bayer For Her' – born from the concern that many women, for a variety of reasons do not talk about their gynecological health and associated challenges. 'Bayer For Her' is an attempt to bring those conversations to the forefront and encourage women to take them up with their doctors. One of the key components is a self-evaluation tool, aimed at identifying heavy menstrual bleeding and endometriosis.



The Bayer For Her Launch:

Together with FOGSI, a 2nd initiative, using a chatbot service "Ask Tanu" was also introduced. The service enables more women nationwide to seek credible and scientifically accurate health information and make informed choices about their sexual and reproductive health. Additionally, Bayer4Health with a presence across social media - Facebook, Instagram and YouTube was launched to deliver credible information for patients and to empower them to learn more about their disease conditions and manage it well with the right medical advice from healthcare practitioners.

To assist local communities access the best healthcare practitioners, we have set up 28 'Phygital' telemedicine centres in 14 aspirational districts across eight states. The key objective of this initiative is to establish a telehealth facility that provides comprehensive telemedicine solutions for local communities and to develop the healthcare infrastructure in the states of Bihar, Chhattisgarh, Jharkhand, Karnataka, Gujarat, Uttar Pradesh, Maharashtra, and Madhya Pradesh. The telemedicine centres are co-located in the Primary Health Care Centres (PHCs). A trained General Nurse and Midwife along with the centre coordinator is responsible for the daily operations of the centre along with the General Physician, who then provides necessary prescriptions. General medicines available in the PHC pharmacy are provided free of cost by the government under the program. As many as 20 different medical specialities are being offered via teleconsultation and training and awareness sessions are also being conducted on health, hygiene, and nutrition. In addition, regularly held medical camps create awareness of specific health aspects like breast cancer, diabetes, and dermatology. The centres are also building awareness on mental health and its importance amongst patients.

## A proud moment that pushes us further!

The Cancer Moonshot is a White House initiative, launched in 2016, to accelerate scientific discovery in cancer research and facilitate new collaborations to offer greater shared data on the same. So, it was an honour for us at Bayer, when our Oncology Sustainability initiatives in India were recognized in the Whitehouse Cancer Moonshot fact sheet! This was issued in conjunction with the Indian Prime Minister, Mr. Modi's official visit to the US in June 2023. As part of the Oncology Sustainability Initiative, Bayer is working with the National Cancer Institute of India-All India Institute of Medical Sciences (NCI-AIIMS), to develop a sustainable model for delivering quality cancer care for the underserved rural population in and around Jhajjar (Haryana).

With targeted screening among high-risk individuals, early disease detection and timely treatment, NCI-AIIMS has launched a screening program for prostate, head and neck/oral cancer with support from Bayer to enhance cancer surveillance in India. An important feature of this collaboration is that patients who are identified through the screening initiative can make use of the Ayushman Bharat scheme of the Government of India to receive timely medical care. The five-year initiative will enable screening of approx. 12,000 patients in the geographical vicinity of NCI.

We have also partnered with Karkinos Healthcare to scale up cancer screening in target communities in Mumbai and Puducherry. The collaboration combines Bayer's vision of "Health for All" and Karkinos' focus on early detection and aims to remedy cancer care disparities in target communities over the next two years. This project aims to screen 100,000 individuals, focusing on cancers including oral, breast, cervix, colorectal, and prostate. The initiative ensures a care continuum by working closely and in partnership with the community and local institutions.

Going forward Bayer will continue to leverage partnerships of all types, to help advance its commitment of making innovative treatments accessible to as many patients as possible, thereby benefiting their health and quality of life.



Supported by Bayer - National Cancer Institute of India-All India Institute of Medical Sciences (NCI-AIIMS), cancer screening program in Jhajjar (Haryana)

## Sustainable solutions across the spectrum

2023 was a significant year for Boehringer Ingelheim India. In December, we marked a milestone, a truly remarkable journey - one that is worth celebrating: 20 years of serving India.

With humble beginnings in 2003, we embarked on this journey with a passionate team of 20 individuals. The following years were about commitment and making strides, establishing ourselves in India. We're not just shaping a healthier future – we're rewriting stories of resilience and hope as we together build a healthier, more sustainable, and equitable tomorrow.

### Two decades of effort & excellence!

From battling diabetes, heart failure, kidney disease and stroke to caring for pets, avian and ruminants, our commitment has remained steadfast. We acknowledge the deep and complex ways the lives of humans and animals are interconnected and work on breakthrough therapies and co-create solutions that help millions of people worldwide live longer, healthier lives. Our commitment to support the communities we live and work in reflects in sustainable initiatives and employee volunteering activities that supports our three pillars of More Health, More Potential and More Green.

Our diverse workforce of now 700+ individuals has fostered a thriving culture that champions equity, fuels creativity, and propels us forward. Boehringer Ingelheim has been honoured with prestigious awards, including the Top Employer certification for two consecutive years in India, Best Companies for Women, and Great Place to Work certification. Additionally, we proudly hold the OPPI Sales Force, HR and Medicine Excellence awards, showcasing our dedication to excellence and innovation.

The challenges we faced together have defined us. We maintained industry leading customer engagement and protected our innovation. Our collective strength, resilience, and unwavering commitment have propelled us forward, setting new standards of excellence.

The theme '20 years of serving India' encapsulated not just the passage of time but also the depth of our achievements and the promise of an even brighter future for the citizens of India. In its pursuit of advancing healthcare innovation and fostering sustainable development across generations, Boehringer Ingelheim has proactively undertaken a series of impactful initiatives that symbolize the organisation's dedication to fostering positive change in communities.

### STOP Rabies: Building the human-animal bond

Did you know that every nine minutes, rabies takes a human life? India is endemic for rabies and suffers approximately 36% of the world's human rabies deaths transmitted by dogs. As dog bites cause almost all human cases, the most effective way to protect humans is by vaccinating dogs. Boehringer Ingelheim's 'STOP Rabies' campaign has made a profound impact in the ongoing battle against rabies. By vaccinating 30,000 uncared-for dogs and cats in the Greater Mumbai area and engaging with over 1,500 school students through comprehensive education initiatives, the campaign reflects the positive impact of integrated efforts.

Through collaboration with the Pet Practitioners Association of Mumbai and Brihanmumbai Municipal Corporation (BMC), Boehringer Ingelheim not only mitigated the immediate risk but also laid the groundwork for long-term preventive measures. This impact resonates not just in numbers but in the lives safeguarded, communities educated, and the tangible progress made towards achieving the National Action Plan for dog Mediated Rabies Elimination (NAPRE) by 2030 and World Health Organization's ambitious goal of zero human deaths from dog-mediated rabies by 2030.

Boehringer Ingelheim's 'STOP Rabies' initiative exemplifies how focused, integrated efforts can bring about transformative change in public health outcomes.





**Partnership with GIZ India's Indo German programme on universal health coverage to support medical innovation and healthcare transformation in the country**

GIZ India's Indo German Programme on Universal Health Coverage (IGUHC) and Boehringer Ingelheim India teamed up to focus on achieving the broad system outcomes of equity, quality, and resource optimization in healthcare. This will be achieved by strengthening systems for health financing, human resources for health, health care technologies, health information, partnerships, sector leadership, policy, and governance, focusing on both communicable diseases and the government priority of managing chronic conditions like diabetes, cardiovascular diseases, and related co morbidities.

Under a Memorandum of Understanding, the partners will focus on supporting health system innovation with global knowledge, improving the institutional structure for evidence based and sustainable health system strengthening, to better respond to health system challenges, while benefitting patients.



**Boehringer Ingelheim's innovation impact: Advancing healthcare solutions**

In alignment with its commitment to innovation and improving patient lives, Boehringer Ingelheim has joined forces with the Startup Incubation and Innovation Centre (SIIC) at the Indian Institute of Technology Kanpur (IITK). The collaboration, underscores a dedication to supporting nationally significant innovations, particularly in healthcare, harnessing the power of technology.

The Memorandum of Understanding solidifies Boehringer Ingelheim's backing of SIIC's Lenek Technologies, focusing on revolutionizing TB eradication through an inventive handheld X-ray device. This strategic partnership aims to enhance the screening process, addressing a critical aspect of TB diagnosis. The collaboration is not merely a technological venture but a mission to create socially beneficial innovations that can catalyze transformative change in the healthcare industry.



**Happy pets: Expansion of our animal health portfolio in India.**

The month of August witnessed Boehringer Ingelheim India expand our animal health portfolio in India with the launch of NexGard® (afoxolaner) product line for small (weighing 2-4 kgs) and medium (weighing 4-10 kgs) dogs. These products come after the successful introduction of NexGard® X and L earlier in 2020.

The tropical condition in India provides an ideal weather for the survival and propagation of flea-borne and tick-borne pathogens in dogs. These can also be easily transmitted from animal to humans, leading to a larger health concern. It is thus crucial for pet parents to be aware of and administer regular parasite control for their pets. With the introduction of NexGard® S and M, Boehringer Ingelheim aims to ensure the same high-quality protection for small and medium-sized dogs, as their larger counterparts.



It is easy-to-administer, and a convenient and effective way to keep pets safe from harmful parasites. Moreover, NexGard® (afoxolaner) is the only product that is FDA-approved to prevent Lyme infections in dogs as a result of killing black-legged ticks.

### Boehringer Ingelheim’s ANGELS initiative: Transforming stroke care across Maharashtra

Boehringer Ingelheim India has embarked on a transformative journey to enhance stroke care services in collaboration with the Public Health Department of the Government of Maharashtra. This strategic alliance is aimed at delivering timely and high-quality stroke care to patients, while fortifying the state’s stroke care infrastructure. Initiated at St. George Hospital, Mumbai, it showcases the commitment of key stakeholders, including the Maharashtra Government, World Stroke Organization, and National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke Punjab.



Boehringer Ingelheim’s ANGELS initiative takes center stage in this partnership, driving efforts to equip hospitals with multidisciplinary stroke teams. The company, in collaboration with the Public Health Department, launched a pilot project in five districts—Thane, Aurangabad, Pune, Nanded, and Amravati—prior to state wide implementation. Through the MoU, hospitals will benefit from capacity-building initiatives, educational materials, standardization tools, consultancy support, and a robust quality monitoring process.

This collaboration underscores Boehringer Ingelheim’s unwavering commitment to grassroots healthcare improvement, reflecting a vision where stroke care excellence becomes accessible to all corners of Maharashtra.

### Echoes of sustainability

Boehringer Ingelheim orchestrated a symphony of sustainability during its internal business sales conference, where over 550 employees celebrated two decades of commitment to sustainable initiatives. This event transcended routine meetings, weaving an emotional tapestry of unity, empathy, and responsibility.

In Kolkata, the ‘City of Joy,’ fruit tree saplings flourished, while eco-friendly paper bags blossomed to combat plastic waste. Bangalore, the ‘Garden City’ and ‘Silicon Valley of India,’ witnessed employees crafting tactile materials for visually impaired children, epitomizing inclusivity. Meanwhile, in Chennai, the ‘Light a Life’ initiative brightened the lives of the Kattunayakkan tribe with assembled solar lamps.

Beyond mere activities, participants embraced sustainability, creating a transformative engagement. The cycle meetings became a shared emotion, resonating with commitment to the environment and society. Boehringer Ingelheim’s symphony of sustainability not only left an indelible mark on the participants but also illuminated the communities touched by their collective efforts.







### Harvesting hope: Boehringer's initiative for tribal progress

Boehringer Ingelheim's commitment to creating a better world extends beyond healthcare, with a transformative initiative aimed at enhancing the lives of tribal women and children in the Dhadgaon Block of Nandurbar District, Maharashtra. This comprehensive effort addresses agriculture, irrigation, livestock, nutrition, and sanitation to uplift over 1200 tribal families.

Tangible positive outcomes are evident, with improved irrigation access, adoption of vegetable cultivation, and livestock development. Notably, a 100% immunization rate in goats and the introduction of 56 Osmanabadi bucks for breed improvement have positively benefitted over 200 families. The adoption of good agricultural practices by 1271 families has significantly boosted cereal crop productivity on 2058 acres of land.

In education, the 'WaSH and ODFs' initiatives achieved a 100% adoption of hygiene habits in 10 tribal schools, benefiting 950 students. The healthcare aspect of the project has achieved an 89% immunization coverage among 1011 women and an impressive 95% adoption of exclusive breastfeeding practices. Furthermore, 80% institutional deliveries by 1214 women highlight the holistic impact on maternal and child health.





This milestone is part of the company's broader 'Carbon Footprint' initiative, aiming for carbon-neutral operations by 2030. It's a proactive step to combat climate change and protect our planet's resources.

This initiative also falls under the 'More Green' pillar of our Sustainable Development - For Generations framework, which aligns with the UN SDGs. We're committed to integrating a "green DNA" into our company culture, fostering environmental protection and resource efficiency.



### Carbon neutral and proud: Boehringer Ingelheim India headquarter

In Boehringer Ingelheim India's sustainability journey the organisation's Mumbai HQ is now 100% carbon-neutral. This achievement reflects the company's commitment to a greener future.

Initiated in 2021, the sustainability efforts included opting for a LEED platinum-certified office space, energy-efficient lighting, 100% green electricity and reduced plastic usage, which contributed to cutting 240 kg of CO<sub>2</sub> emissions.

Thanks to these efforts, the company was awarded the carbon neutrality certificate.

## Transforming patients' lives through science

Bristol Myers Squibb (BMS) believes in the power of science to address some of the most challenging diseases of our time. Each day, BMS employees around the world work together for patients – who are at the center of everything we do. The company is proud of the advancements made in oncology, hematology, immunology and cardiovascular disease, and is dedicated to helping patients prevail over serious diseases through our diverse and promising pipeline and new scientific platforms. BMS recognizes that its responsibility goes beyond medicine. The company promotes health equity globally and strives to increase access to life-saving medicines for populations disproportionately affected by serious diseases and conditions.

Bristol Myers Squibb has been committed to India for more than 25 years and the company's continued investment highlights the ongoing importance of its role in our global business. In Bangalore, in partnership with Syngene International, Bristol Myers Squibb employees in R&D work daily to support target identification, lead discovery and optimization and more. In Mumbai, we have been providing medicines to support cancer patients for over a decade. Our \$100 million investment in Hyderabad will bring over 1,500 Bristol Myers Squibb employees together across IT and Drug Development to enhance our innovation capabilities for patients everywhere.

### Better treatments, better outcomes.

India has the largest number of children with Thalassemia major in the world (~150k)<sup>1</sup> and ~42 million<sup>2</sup> carriers of the  $\beta$  thalassemia trait. It is estimated that around 10,000 new babies are born with thalassemia major every year in India. To address this huge unmet need, BMS India launched Rojuzda® (Luspatercept) to serve the adult B-Thalassemia and Lower Risk - Myelodysplastic Syndrome (LR-MDS) patients in India in March 2023.



BMS India Team celebrating the product launch

Disclaimer : The article published in this dossier is for education and information purposes only. Products mentioned in this article are for the use of Registered Medical Practitioner or Healthcare professionals only.

1. Saha, S., Ghosh, S., Basu, K. et al. Prevalence of  $\beta$ -haemoglobinopathies in Eastern India and development of a novel formula for carrier detection. *J Hematopathol* 13, 159–164 (2020). <https://doi.org/10.1007/s12308-020-00407-7>  
 2. Thiyagarajan A, Bhattacharya S, Sharma N, Srivastava A, Dhar DK. Need for a universal thalassemia screening programme in India? A public health perspective. *J Family Med Prim Care*. 2019 May;8(5):1528-1532. doi: 10.4103/jfmpc.jfmpc\_90\_19. PMID: 31198708; PMCID: PMC6559078.

## Bristol Myers Squibb expands global footprint in Hyderabad, with Drug Development and IT & Digital Innovation Capabilities

Bristol Myers Squibb one of the world's largest biopharmaceutical companies, announced the opening of a new facility in Hyderabad in February 2024. The state-of-the-art site will expand the company's global drug development and IT & digital capabilities and is expected to be home to over 1,500 employees.

The new site expands Bristol Myers Squibb's global footprint and will serve as an innovation hub, as the company writes the next chapter in its history. The company has invested over \$100 million in the creation of this cutting-edge facility.

The innovation hub in Hyderabad will accelerate drug development and enhance Bristol Myers Squibb's digital capabilities. It will help Bristol Myers Squibb further diversify their global workforce by adding world-class local talent and strengthening the ability to positively impact patients everywhere. The diverse talent pool ranging from specialization in information technology, medical writing, regulatory process and statistical programmers, operations besides physicians, will help global drug development process as well as IT processes.



Inauguration of new Bristol Myers Squibb site in Hyderabad by the Honorable Minister for Industries & Information Technology of Telangana, Mr. D. Sridhar Babu and Christopher Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb

## Improving the Global Clinical Trial footprint in India

Bristol Myers Squibb is united by our mission to transform patient's lives through science by discovering, developing, and delivering innovative medicines that help prevail over serious diseases. To that end, the company is committed to doing its part to help ensure patients achieve optimal health outcomes.

We are working to improve the recruitment of diverse patients with the goal that the clinical trial population becomes more reflective of the real-world population and the people impacted by the diseases studied.

In 2023, India participated in 16 Clinical Trials across indications in therapies including Oncology, Hematology, Cardiovascular and Immunosciences. India's participation in these global trials will go to benefit Indian patients in the future.



## Project ECHO : Strengthening healthcare infrastructure

BMS has supported Project ECHO (Extension for Community Healthcare Outcomes) through independent charitable grants since 2022. Project ECHO helps empower rural healthcare providers with expert knowledge and best practices, and support programs around the globe in responding to community-specific health needs, such as revolutionizing cancer care in rural and vulnerable areas and combating the spread of COVID-19 in nursing homes. Currently, Project ECHO is implementing a training curriculum in India for the prevention, screening, treatment and psychological support of individuals affected by beta-thalassemia in India. With the support of BMS, Project ECHO is educating 350 doctors and upskilling 1,000 allied health workers.

## Bristol Myers Squibb R&D center in Bangalore

Bristol Myers Squibb has an extensive R&D center in Bangalore. The Biocon Bristol Myers Squibb Research & Development Center (BBRC) is a collaboration between Bristol Myers Squibb and Syngene International, a Biocon-group company. Fully operational since 2009, the site is involved in Target Identification, Lead Discovery, and Lead Optimization all the way through to early-stage Pharmaceutical Development and Clinical Biomarkers R&D. Close to 1000 people are involved in different activities in the R&D center.



Supporting The Akshaya Patra Foundation (TAPF) PM POSHAN (Mid-Day Meal) Programme



## BMS contributions empowering communities

BMS India demonstrated its commitment to corporate social responsibility in 2023 by supporting various programs related to health, nutrition, disability, and education in collaboration with esteemed partners like Akshaya Patra Foundation, Janyaa Foundation, Shree Bhagwan Mahaveer Viklang Sahayata Samiti (Jaipur Foot), IIT Hyderabad, and Project Poshan (United Way of Mumbai)



Skill Development Program supported by BMS with IIT Hyderabad





## Lilly India – Creating medicines to make lives better

Lilly started its operations in India 30+ years ago and has a strong history of bringing innovative products in the areas of diabetes, oncology, and immunology to the country. Lilly currently operates in India through two business entities: Lilly Pharma (HQ: Gurgaon) and Lilly Capability Center India (HQ: Bangalore).

### New discoveries bring new hope

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step towards a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more - visit <https://www.lilly.com/in/>, follow us on LinkedIn - <https://www.linkedin.com/showcase/lilly-india/>

### Step Up school –Established by Lilly

**Step Up school for underprivileged:** Lilly took this initiative in year 2014 with the objective that Step Up becomes an ideal Lilly school for underprivileged children, to impart the basic education and set up a platform for these children to enter the mainstream educational system. Approximately 788 children have been educated in Step Up centre, 357 have been mainstreamed into regular school through Kadam program and 330 children have been provided digital literacy.

The school works with 209 children from underprivileged backgrounds through the following programs –

- 1) **KADAM:** The Step Up Project (6 – 14 years): Within the program the project staff identifies drop out and out-of-school children from the community, enrolls them into Kadam centres, where they are brought to their age-appropriate learning level, using the Kadam methodology and then are mainstreamed into government schools
- 2) **Pre-School of the Future (PoF):** Aims to provide education and care to children within the age groups of 3-6 years. 71 Kids have mainstreamed through POF program
- 3) **Samarth Program:** Aims to provide remedial educational support in the form of tuition classes in after school hours to children. Approximately 30 Children Passed out from 10th Grade through Samarth Program
- 4) **Digital Literacy Program:** A 3-month basic computer course to make children computer literate

The school also runs the Mid-day Meal which is being provided to the children at the centre through Akshaya Patra Foundation. The aim is to provide a nutritional meal to the children while they are at the centre and try and eradicate malnourishment.



## Global Day of Service

GDOS is one way Lilly connects thousands of employees to each other and their communities through volunteerism. Each year, Team Lilly comes together on this one day at every level of the company, in more than 65 countries, investing their time and talent through giving in ways that are meaningful to them and advancing their purpose – to make life better for people around the world. Last year in September, thousands of Lilly employees around the world united to go beyond business and unite to serve communities during their 16th annual Lilly Global Day of Service (GDOS) - one of the largest single-day volunteer programs of any global enterprise. Lilly India team did a range of educational and engagement activities with Step Up school, brought smiles to homeless elderly people in a shelter home and also participated in a forest plantation drive for a greener future.



## Lilly Patient Support Program – convenient solutions to patients

With Lilly Patient Support Programs (PSPs), the company supports patients in navigating medication access, adherence and other support challenges throughout their disease journey. Through each PSP conversation, interaction, and touchpoint, Lilly strives to improve patient outcomes. Keeping the patient in mind, Lilly has ensured responsibility to appropriately govern PSP activities to ensure the protection of patient safety, ethically manage the collection and use of personal information, and accurately collect and report Adverse Events and Product Complaints.

- Appropriate information on availability and price
- Trained executives for patients
- Executives with 4 language proficiency in English, Hindi, Bengali and Malyalam
- No IVR (Interactive Voice Response)-Live executive to attend patients
- Neutral outsourced non-commercial team
- All India Toll-Free Number
- Auto-call back facility for out-of-office hours/days



## Ferring's FDG technology: A game-changer in convenience and effectiveness

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people build healthy families and live better lives. Founded in the 1950's, we quickly gained reputation for our innovative treatments for mothers and babies and became a market leader in reproductive medicine and maternal health, as well as in specialty areas within gastroenterology and urology. Today, we are a global company with over 7,000 employees in more than 50 countries, with 15 manufacturing sites and 11 R&D centres, serving markets in over 100 countries.

### Expertise, Experience & Effectiveness.

At Ferring we harness our world-leading expertise and collaborations to apply new science to unmet needs across our key therapy areas. Our five main areas of research to advance outcomes for the public are: reproductive medicine & maternal health, gastroenterology, urology, microbiome, and early-stage development.

Ferring invests heavily in the process of creating new medicines through its research and development centers and through research collaboration with scientific institutes, as well as biotechnology and pharmaceutical companies throughout the world. We strive to maintain our leadership by:

- Focusing on novel peptide-based drugs and biotechnology-derived medicines, such as recombinant proteins and other biologics
- Investing in cutting-edge science and technology
- Adapting existing peptide-based medications to meet specific medical needs.
- Developing effective and patient-friendly drug delivery systems.

In our relentless pursuit of innovation, Ferring Hyderabad Product Development Centre (FHPDC) introduced fast dissolving granules (FDG) technology in the year 2023. Multiple products are under development but two molecules Sildenafil and Solifenacin are approved in India for erectile dysfunction and overactive bladder respectively.

FHPDC is an integrated R&D and manufacturing facility inaugurated in April 2022 in Hyderabad's genome valley, has unique capabilities in formulation development, packaging, and analytical development. We have a group of over 40 scientists working continuously to address multiple unmet medical needs.

### FDG technology offers multiple benefits like:

- Ease of administration, no water needed.
- Fast dissolving
- Taste masking
- High patient compliance
- Applicable to all age groups



Ferring Hyderabad Product Development Centre

With the intention of maximizing the reach of products to patients and HCP's, Ferring India decided to partner and Co market the products with Corona Remedies and signed the agreement in September 2022. Both Urology molecules formulated in this innovative dosage form based on Ferring's propriety technology will offer great convenience to patients.

The success of these products launched through Innovation from India for India has encouraged us further. We now have plans to share this innovation globally. Ferring will take these products to multiple other countries, where millions of patients will be immensely benefited, too.





## A century of commitment, a legacy of trust

UK-headquartered GSK plc is a company with a long legacy of impactful solutions to scores of serious conditions. And GlaxoSmithKline Pharmaceuticals Limited, its subsidiary in India, has proudly followed in the same footsteps! With its focused purpose to unite science, talent, and technology to get ahead of disease together, the company has a 100 year-long and strong association with the country. As GSK enters the centenary year of its legacy in 2024, we are ever more committed to deliver on our purpose to positively impact patients' lives, continue to build trust established nearly 100 years and deliver value with the support of all our stakeholders as we #LeadTheNextTogether

### A mammoth mission; a dedicated workforce!

In the year 2000, we took up the worthy cause of eliminating lymphatic filariasis (LF). In this mission's almost-quarter century, and our company's India journey of a century, we stand even-more determined towards this cause, today. Commonly known as elephantiasis, LF is a painful and profoundly disfiguring disease, with far-reaching social and psychological consequences. It is the leading cause of permanent disability worldwide.

Partnering the World Health Organization (WHO), GSK has been driving mass drug administration (MDA) in affected areas. The company supplied 44.5 million albendazole tablets in 2023 alone towards this cause! Having distributed nearly 3.96 billion tablets till date, GSK has pledged to provide the same for as long as is needed to eliminate LF.



### GSK Scholars

Continuing to play a part as a responsible corporate citizen, the company launched 'GSK Scholars', a flagship community initiative. This programme enables meritorious, but financially disadvantaged students, to study medicine from government medical colleges. Under this scholarship, a sum of up to INR 1,00,000 is granted every year, over a four-and-a-half-year period, to cover the academic expenses incurred for the MBBS programme. Through this programme the company aims to make STEM education more accessible in the country benefiting nearly 400 beneficiaries.



## Education for All

This initiative aims to transform select classroom into smart classes in Nashik , Maharashtra . Under this initiative , we have promoted digital education through smart class for grade 5-10 students impacting over 7500+ beneficiaries across 54 government -run schools with the focus to improve the academic performance and attendance of students.



## Engaging with local communities, protecting natural resources.

GSK India is working with local community organisations on water basin replenishment and water access projects. GSK India has partnered with Watershed Organisation Trust (WOTR), to work with rural communities, to deliver long-term water volume reduction in the Nashik water shed manufacturing facility and improve health and education of local families in the basin. We are a founding partner of the Women + Water Collaborative in India, working with the Water Resilience Coalition—an initiative between the United Nations Global Compact and the Pacific Institute. This program brings together companies from different sectors to leverage women’s leadership to improve access to clean water and sanitation, ultimately supporting the health of local communities.

## Launch of new products and campaign

GSK India launched Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in April, for the prevention of Shingles (herpes zoster) and post-herpetic neuralgia in adults aged 50 years and above. Shingrix is the world’s first non-live, recombinant subunit vaccine to be given intramuscularly in two doses. Shingles is caused by the reactivation of the varicella zoster virus (VZV), the same virus that causes chickenpox.



## Amitabh Bachchan partners with GSK for Shingles awareness and prevention

GSK’s latest campaign film highlights the painful disease of Shingles and its risk in adults above the age of 50 and the possibility of prevention. The campaign film evocatively captures the agonising pain caused by shingles and its debilitating impact on the people living with it. It gives an important message that it is possible to protect ageing adults against this pain through vaccination.

## 7 Star Protection

The 7 star protection campaign was launched with an intention to involve, educate and make parents aware of the relevance and importance of 7 vaccinations recommended by the Indian Academy of Paediatrics (IAP), targeting children in the 1-2-year age group.



## Annual Flu Vaccination

The campaign focused on creating awareness about the importance of annual flu vaccination and emphasised its importance for people at high risk of contracting disease during seasonal changes.

## We help create, improve and prolong lives


At Merck, Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. We make a positive difference to millions of peoples' lives every day. Our constant curiosity and specialist approach drive our partnerships and bring new ideas to life.

In India to meet the patient demands and adapt to the dynamics, we ensure to accelerate and expand access of innovative medicines to patients: driving pipeline projects, maximizing our existing portfolio, and expanding further in emerging markets.

**Merck Healthcare India**  
**in India, FOR India and FOR the world**

**Advancing Science**  
1000+ team of Commercial & R&D

**Accelerating Access**  
Govt. Partnerships and Digital health solutions



**Maximize India Opportunity**  
Treat today's and future patients

**Harness the talent footprint and technological advances**

### OUR EXPERTISE

#### FERTILITY

Scientific leaders with complete portfolio

#### CARDIOVASCULAR, METABOLISM & ENDOCRINOLOGY

Concor – ranks no.1 Beta blocker brand

#### ONCOLOGY

Erbitux among top 5 Oncology brands

### Bringing global innovation to India

Merck is accelerating to bring global innovations in the country, ensuring swift access to the highest standard of care for patients.



#### Oncology:

Bavencio is launched for 3 indications - Urothelial Carcinoma, Renal Cell Carcinoma, and Merkel Cell Carcinoma. India becomes first country in the world to launch all three indications of Bavencio® at once.



Tepmetko is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring MET tyrosine kinase receptor exon 14 (METex14) skipping alterations.



#### Fertility:

Pergoveris® Pen is the first-ever product with a combination of recombinant Follicle Stimulating Hormone and recombinant Luteinizing Hormone in a ready-to-use device to be used upon prescription by an IVF specialist.



#### Cardiovascular:

Concor T, combination medicine used in the treatment of hypertension (high blood pressure)

### Innovative patient care initiatives leveraging digital technology

Our intent has always been to improving patient lives, and with our cardio franchise, we have taken this a step further. Thanks to an innovative packaging solution, embedded with a QR code. Hypertensive patients or family members can scan the code, enabling immediate information about their condition, thereby educating them as well.

Hypertension awareness digital info





By harnessing our digital capabilities, we are elevating awareness and expanding access by introducing a portal <https://umeed.headandneckcancer.co.in/> that provides comprehensive information on Head and Neck and Colo Rectal Cancer. Umeed, meaning "Hope," stands as a Merck initiative aimed at expanding access and awareness for patients with Head & Neck Cancer and Colo Rectal Cancer in India.

As market leaders in fertility, we remain unwavering in our commitment to supporting patients throughout their treatment journey. Thus, we launched a one of its kind patient support portal 'www.IVFSathi.com', designed to empower patients with self-administration using innovative Pen devices.



## Building inclusive organizations through DE&I

### Empowering future Women in Leadership

Merck partners with Unlurn to launch 'VOICE' program – a leadership program for women. Aims to awaken women to their innate leadership capacities, through an inside-out, awareness-based approach

Media coverage - <https://hr.economictimes.indiatimes.com/news/hrtech/talent-acquisition-and-management/how-merck-india-is-trying-to-achieve-gender-parity/104003215>



### Launch of Fertility benefits program


Merck launches fertility benefits program for Employee. The new Fertility Benefit offer applies to Merck employees, irrespective of their marital status, and is also open to their partners.

Media coverage - <https://benefits-expert.com/merck-unveils-new-fertility-benefits-employees/>



## Innovations to drive sustainability goals

### Ecological friendly logistics and reuse of shipping material



### Innovative packaging reducing carbon footprints



### Modernized warehouse and supply operations



## Reimagining medicines and championing patient engagement

Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious diseases. Our medicines reach more than 280 million people worldwide.

### Build sustainable partnerships with patient organizations

The Alliance & Partnerships for Patient Innovation & Solutions (APPIS), initiated and funded by Novartis in 2021, addresses health disparities in the Asia Pacific, Middle East, and Africa. Engaging over 2,000 participants from 60+ countries, including patient organizations, policymakers, and innovators, APPIS focuses on collaborative efforts through initiatives like the APPIS Summit, Innovator Program, and local APPISx. In India we have embraced APPIS, with the same aim. In 2023, APPISx India had two main events focused on Cardiovascular and Oncology patient organizations, bringing to life a three C strategy– Capability building aimed at empowering more purposeful and effective participation of patients in the overall healthcare system strengthening, Collaboration for multi-channel disease awareness, and Co-creating impactful tools to drive impact for patients.

APPISx India 2023: Workshop with Breast Cancer Patient Leaders to build a quality of life (QoL) measurement tool



In a novel approach this year, APPISx India facilitated impactful discussions, bringing together UNBLOCKED ambassadors – six patients and caregivers underwent extensive training, aiming to champion the cause of better heart health in India and a breast cancer Wellbeing Tracker co-created by patient organizations. These initiatives underline APPIS' commitment to fostering dialogue, building capabilities, and co-creating solutions, ensuring a resilient and hopeful future where patient stories resonate, leaders find strength, and positive change illuminates the horizon of healthcare.

APPISx India 2023: Capability Building with Unblocked Ambassadors from India



### Returning to society

Novartis in India with its CSR (Corporate Social Responsibility) endeavors in 2023, moved towards 'championing sustainable livelihoods' and empowering communities to be happier, healthier and more independent. We have had the privilege of impacting over 1,00,000 lives in the year via 7 projects.

### Watershed development project towards water neutrality

India has many water-stressed communities that rely on agriculture as their primary source of income. Many of them are trapped in a vicious cycle – no water leads to a loss of income and health, which in turn furthers the inability to access water.

Together with the National Agro Foundation, Novartis has developed a project to improve access to water in 12 rural villages across 2 districts in Telangana, India. This project has adopted a 360° model of support – increasing water supply, improving efficiencies in water utilization, encouraging community development and enabling opportunities for income generation.

Novartis has been able to neutralize 100% of its water consumption in India while impacting 11,000 lives. We have developed 24 water structures, seen water storage creation of 100,000 m<sup>3</sup> and planted more than 9,000 trees. The community has seen an average increase in income of 10%. Beneficiaries have seen their businesses grow, incomes rise, and health improve, resulting in happier and healthier communities overall.

Building a dam – the change from 2021 to 2023



Desilting a river – the change from 2021 to 2023



The impact on the community



## Kyzific® Launch in India

### Over two Decades of Pioneering Innovation in CML and Beyond

With a breakthrough approval 23 years ago, Novartis opened the door to reimagine CML and other cancers. The pursuit of bold science didn't stop there. In May 2001, Novartis received approval from the US Food and Drug Administration (FDA) for the first targeted therapy for cancer, known as a tyrosine kinase inhibitor (TKI). This was a watershed moment in drug discovery, transforming the treatment landscape for chronic myeloid leukemia (CML), and opening the door to reimagining possibilities for other forms of cancer and blood disorders.

Novartis India received the market authorization for the molecule *Asciminib*® (brand name: *Kyzific*®) in India in October 2023. The molecule was launched to the community of health care professionals in the country at the two major conferences – 3rd Indian Cancer Congress and 64th Hematocon 2023, engaging a total of over 7,000 oncology professionals in the country.



Kyzific® launch at the 3rd Indian Cancer Congress (ICC).



Kyzific® launch at the 64th Hematocon 2023

## Sybrava® Launch in India

### Over three decades of reimagining medicine and improving the heart health of people across the world

Novartis has a strong legacy of reimagining medicines for over 250 years and continues to make substantial and ongoing investments in research and development to create innovative medicines that address the evolving needs of patients, healthcare professionals and society. For over 30 years Novartis has been instrumental in transforming the standard of care for cardiovascular diseases (CVDs) which is world's leading cause of death claiming nearly 18 million lives each year<sup>1</sup>. Sadly, India accounts for one-fifth of these deaths owing to CVDs, worldwide.<sup>2</sup> Coronary Artery Disease (CAD) occurs at a younger age in Indians with over 50% of Cardiovascular Disease (CVD) mortality occurring in individuals aged less than 50 years.<sup>3</sup>

Elevated LDL-C or 'bad' cholesterol is not only an important risk factor for CVDs, but also the cause for Atherosclerotic cardiovascular disease (ASCVD)<sup>3</sup>.



Novartis also had a session with Professor Borge Nordestgaard from Denmark, who presented at CSICON'23 on 'LDL-C reduction in Acute Coronary Syndrome: Strike Early, Strike Strong' along with leading cardiologists like Dr JPS Sawhney, Dr. Prafulla Kerkar and Dr. Ashwani Mehta who presented on strategies on Lipid Management.

#### References

1. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. *J Am Coll Cardiol.* 2020 Dec 22; 76(25): 2982–3021
2. Kumar, A. Sreenivas, and Nakul Sinha. "Cardiovascular disease in India: a 360 degree overview." *medical journal armed forces India* 76.1 (2020): 1-3.
3. Dalal, Jamshed, et al. "Vascular disease in young Indians (20-40 years): role of ischemic heart disease." *Journal of clinical and diagnostic research: JCDR* 10.9 (2016): OE08.

We are happy to receive import and marketing permission for Sybrava® (brand name for Inclisiran in India), a first-in-class siRNA therapy for LDL-C-lowering by the DCGI office and have launched this innovative medicine in India. This innovative medicine has the potential to change the practice of medicine in treating ASCVD patients. We are constantly seeking opportunities to partner key stakeholders like the Government, insurance companies and healthcare providers; to find sustainable access strategies based on value-based reimbursement and evidence-based decision making to ensure that advanced therapies like Inclisiran can improve health outcomes of people in India.

In December 2023, we conducted a soft launch of Sybrava at the Cardiological Society of India (CSI) Conference in Kolkata. This conference is the largest convention for cardiologists in India and saw attendance from leading cardiologists from all across the country.

## Reimagining cancer care in India

Novartis in collaboration with Network18, one of India's largest media conglomerates, Tata Trust and Federal bank is bringing to life Sanjeevani – United against cancer. This is a large-scale initiative aimed to spread awareness and break stigma and fear about cancer amongst the Indian population. The intention is to emphasize that it's never too early to learn about cancer and the importance of regular breast self-exams and mammograms, empowering them to detect potential issues early on.

Together, we launched this initiative in October 2023, during breast cancer awareness month. The aim was simple – to deliver a message of hope and encourage action. This journey started with two on-TV discussions with esteemed panelists showcasing beautifully touching stories of facing cancer with positivity and grace. The shows then went on to delineate the need to ignite a movement to drive screening and also discussed the improving treatment paradigm for cancer. We are looking forward to strengthening this partnership and impacting many more lives going ahead.



Launch of Sanjeevani in light of World Breast Cancer Awareness month in October 2023 in the National Capital Region

## Unblocking India's heart health through sustained partnership

Novartis, in collaboration with The Times of India, has been at the forefront of transforming cardiovascular care in India. Their initial initiative, 'Beat Heart Failure,' achieved remarkable success by garnering support from 11 state governments and elevating India's contribution in global Google searches about heart failure from 0.7% to over 27%. Now, expanding their commitment, Novartis, along with The Times of India, is launching the "Unblocked Movement." This initiative aims to raise awareness about the importance of "Beating Bad Cholesterol" for maintaining unblocked hearts in India. Through sustainable partnerships with the healthcare ecosystem, the movement brings together patients, loved ones, healthcare professionals, and systems to break barriers and improve heart health outcomes.

In addressing the absence of a dedicated heart health patient group, Novartis utilized AI-enabled social media listening to identify Mr. Ram Khandelwal, a passionate cardiovascular disease advocate. Ram, through his Facebook community, played a crucial role in raising awareness about heart health in India. Furthering their commitment, Novartis organized the APPISx India Chapter, tailoring alliances and partnerships. This chapter led to the establishment of one of India's first patient heart group, the 'Heart Health India Foundation,' now an officially registered NGO actively working on various platforms and developing a patient referral program with the guidance of an advisory panel of esteemed doctors.





## Driving change to defeat serious chronic diseases

For pharmaceutical giant Novo Nordisk, a hundred-year-old company, there has always been just one mission: to provide access to affordable medical care and offer innovative solutions to millions of people living with serious chronic diseases globally. The company, known for its treatments for diabetes, obesity and rare blood and endocrine diseases, leverages its vast expertise in these areas to improve the lives of these patients. Novo Nordisk produces more than 50% of the insulin used in the world today!

The company has a laudable ambition: to prevent more than 100 million people from getting type 2 diabetes by 2045. Thus, the thrust of their social responsibility strategy focuses on three critical areas: preventing the rise of type 2 diabetes and obesity, providing access to affordable care for vulnerable patients and driving innovation to improve lives. The company is also determined to strengthen the healthcare system for type 1 diabetes, especially for underserved patients.

### ESG The Novo Nordisk Education Foundation

Cementing its commitment towards managing Type 1 diabetes (T1D) among children in India, the Novo Nordisk Education Foundation (NNEF) inaugurated 10 Centres of Excellence in India.

As a public-private partnership, all CoEs will cater to the immediate need of building capacity and capability to fulfil the unmet needs of people living with T1D in the country. They aim to provide holistic care through a host of services, including a dedicated dietician for consultation, doctors for regular health check-ups, diabetes monitoring, laboratory tests, and efforts to strengthen the overall T1D care ecosystem, through capacity and capability building.



### Future Scientist Summer Camp

Novo Nordisk hosted a one-of-a-kind summer camp, which witnessed 100 exceptional children from all over the world coming together to face intriguing questions that make them stop and think and try to solve complex problems through collaboration and scientific experimentation at the state-of-the-art Novo Nordisk facilities and LIFE Campus in Copenhagen, Denmark.



## Corporate Social Responsibility

In alignment with their steadfast dedication to social responsibility, the Novo Nordisk team has actively engaged in meaningful activities, including organizing beach clean-ups in Mumbai, extending heartfelt visits to local orphanages, and fostering connections with residents in old age homes. These initiatives reflect their sincere commitment to making a positive impact on the communities they serve.



## Marathons, Cyclothon and Wellness Campaigns

Novo Nordisk prioritised employee well-being by organizing engaging events such as cyclothon, marathons, and wellness campaigns. These initiatives not only fostered a sense of community and teamwork but also promoted physical fitness and mental well-being among employees. By encouraging active participation, the company demonstrated its commitment to supporting a healthy and vibrant work environment.



## Campaigns and Disease Awareness Activities

### World Haemophilia Day

Novo Nordisk has diligently pursued initiatives aimed at raising awareness of rare diseases, as demonstrated by its comprehensive engagement on World Haemophilia Day”

### #weightofdiabetes campaign

The GLP-1 team ran a campaign called the Weight of Diabetes with the aim of spreading awareness across key stakeholders and encouraging the exploration of newer possibilities in diabetes management. In Q1 2023, a comprehensive #WeightofDiabetes disease awareness campaign spanned Delhi, Bangalore, and Mumbai. Targeting key stakeholders, it aimed to promote new approaches to managing diabetes through the press, social media, a patient info center, and on-ground events.

### Outcomes:

- Engaged 4500+ Healthcare professionals in scientific dissemination
- Reached a press readership of 830+ million
- Conducted 3 camps, analyzing body composition for 2000+ individuals across the three cities
- Reached over 30 million patients on Social Media with a 9.7% average engagement rate
- Achieved 1 million+ video views of the Brand ambassador's hero movie, with a 65% positive sentiment.

## Quality. Trust. Wellbeing.

Otsuka Pharmaceutical India Private Limited (OPI), based in Ahmedabad, is the fully-owned subsidiary of Japanese MNC Otsuka Pharmaceutical Factory (OPF). Powered by the 100+ years of Otsuka's legacy of Quality, we are one of the leaders in intravenous nutrition products in the country. We are also known for our range of medicines for psychiatric diseases, neurological diseases and oncology. Our customer base includes government institutions, large corporate hospitals, and nursing homes.

### New Products, People-Centric activities, and more...

The year 2023 was a landmark year for Otsuka Pharmaceutical India Pvt. Ltd. (OPI), as we completed 10 years of our inception. We also launched important products across therapies, further strengthening our product portfolio.

OPI is determined to take it forward by being a worthy contributor to its vision of the holistic well-being of the world we live in. As part of its CSR activities this year, the company has focused on the well-being and welfare of the environment and the people. This included an Annual Health check-up of its employees, distribution of school bags to the students in the vicinity, a tree plantation drive, and a one-week-long Yoga camp for employees. As part of its Go Green initiative, OPI planted trees at the Prakash School for the Intellectual Disability- Boys and had a heart-warming interaction with the special, enthusiastic, and energetic children of the school.

With this New Year, OPI is stepping into a new era, a new decade of sustainable growth that benefits the environment, the people, and the business all the same.


### Go Green With Otsuka – Tree Plantation at Prakash School for Intellectual Disability- Boys



### School bag distribution – By OPMF Team



New Products Launched in 2023



Health Check-ups of CO and DS employees



Yoga



A Decade of Otsuka Quality in India



## Getting closer to our communities through 'SEHAT'

Procter and Gamble Health Limited started operations in India in 1967, and there has been no looking back since! We soon grew to become one of India's largest VMS companies manufacturing and marketing vitamins, minerals, and supplements. Our trusted products are household names in India, supporting millions of people to live healthier and more fulfilling lives.

### Getting Closer symbolizes our commitment.

To being there; for our consumers and patients when and where they need us, to bridging the gap between cutting-edge scientific research and patient care, to extending healthcare to our communities and to serving and caring for our own.

Through SEHAT, our flagship CSR initiative, P&G Health is committed to contributing towards building a healthier India, strategically addressing 3 aspects of Public Health: Capability, Accessibility, and Intervention through 8 bespoke programs in collaboration with reputed NGO partners across India.

#### CAPABILITY

##### SEHAT Scholars Program

PGHL instituted the 'P&G Public Health Scholarship' for deserving students from socially & economically disadvantaged communities seeking to pursue 'Master's in Public Health'. In 2022-23 session, 61 new P&G Health Scholars initiated their career in public health across the five Indian Institutes of Public Health (IIPHs) across India.



#### Women In Healthcare Scholarship

To encourage more women to pursue a career in healthcare, P&G Health instituted the Women in Healthcare scholarship to deserving female students from 3 pharmacy colleges in Maharashtra & Telangana.

#### Infra upgradation projects

Continuing our efforts to upgrade school infrastructure in villages around our manufacturing site, to facilitate the growth of the community and their quality of life, we supported the construction of new classrooms at St. Joseph's High School in Usgao village in Goa.

#### ACCESSIBILITY

##### Gift Of Health – Children

P&G Health continues to be healthcare partner of 2200+ children residing at 56 Child Care Institutes (CCI) across Maharashtra, Goa & Madhya Pradesh. Each child is being supported with a daily-use hygiene kit and sensitized for personal hygiene, preventive healthcare, and other general well-being practices.



## Gift Of Health – Elderly

The aim of our flagship program, SEHAT is service to the community through public health. And one area where access to quality healthcare is very limited, is the disadvantaged elderly population. Unfortunately, they form a major section of society. Under SEHAT, we continue to support the Mobile Healthcare Units deployed at Puri, Guwahati, Chennai & Khandwa (MP).



## Yes To Poshan

Malnutrition is a serious concern amongst pregnant women and young children. With an aim to reduce severe acute malnutrition (SAM), wasting & stunting through small dietary changes amongst the pregnant & lactating women of NTR district in Andhra Pradesh, we launched a special nutritional recipe book this year. It has been curated for expecting mothers and was made accessible to all Anganwadis of NTR district.



## INTERVENTION

### 'Swasthya Sakhi' Program

P&G Health's Maternal & Child Health Community Project 'Swasthya Sakhi' (Health Companions) - contributing to employment, entrepreneurship and access to affordable screening, diagnostics & digital health- continued to take point-of-care diagnostics to remote and underserved locations in Uttar Pradesh, Goa and Madhya Pradesh. Swasthya Sahayak - a portable/backpack sized point-of-care information gathering & diagnostic tool - was deployed to seek and digitize health information of families including conducting diagnostics of pregnant women and referring high-risk cases to Primary Health Centres.



### Maternal & Newborn Health – Urban Poor

Access to affordable diagnostics continues to be a major hurdle for the underprivileged pregnant women in urban communities of India; with public health care centers being unable to cater to the burgeoning numbers. P&G Health's Maternal and Newborn Health program aims to strengthen antenatal care services through the use of technology for early identification of pregnancies and high-risk cases to ensure they receive timely care and support. The project outcome was remarkable as it completed its first year and ensured 99.54% institutional deliveries for the registered mothers.



### PHC cares - support for pharmacy waste segregation and management

P&G health reinforced its commitment to responsible waste management through a first-of-its-kind partnership with Lakshya and Recycle India Foundation for waste segregation and management among pharmacies in India. The program promotes waste management policies through on-ground awareness campaigns for pharmacy owners and staff members on the necessity of and appropriate methods of segregation, disposal, and recycling of waste material in a responsible manner.



## In India, for India and the world

Since India became a Republic, through our portfolio of breakthrough therapies, our cutting-edge global research and development capabilities, our worldclass manufacturing and R&D facilities, we have been growing with India - from strength to strength.

### Pfizer has been in India since 1950 with the launch of the company's India headquarters in Mumbai.

Committed to strengthening health systems, we fuse the best scientific minds with superior research technology to treat and cure some of the most feared diseases prevalent. Today, we are among the largest global biopharma companies in the country with a comprehensive presence across the value chain.

### The very best of our science - over 300 products that change patients' lives in India.

Our portfolio in India includes over 300 products across 16 therapeutic areas under six key business categories – Vaccines, Oncology, Internal Medicine, Anti-infectives, Inflammation & Immunology and Rare Diseases. From the best-known brands in India – like Gelusil, Becosules and Mucaine to India's leading vaccine, Prevenar 13, and niche therapies for Cancer, multi-drug resistant infections and rare diseases like Hemophilia, we have been bringing the very best of our science to help tackle some of the most challenging diseases in India.

### India has the second highest number of Pfizer's own manufacturing facilities (after the US) in the world.

India has emerged as one of the most significant manufacturing hubs for Pfizer in the world. Through a network of 3 Pfizer and 18 partner sites, around 680 crore (6.8 billion) Pfizer pills and vials are made in India each year. That is almost 1.86 crore every day, for India and 120 countries across the world. More than half of our entire India portfolio is made right here, in India.

In addition to developing next-gen molecules, manufacturing life-saving medicines and delivering them into the hands and arms of Indians, in 2023, we have been focused on building a healthier India through our community outreach and patient-focused programs. Providing best-in-class education to help patients and caregivers take control of challenging health conditions and strengthening the healthcare ecosystem in India have been some of our key priorities this year.

### Inspiring better health outcomes:

To mark World Cancer Day, we launched #KeepFighting KeepWinning, our inaugural in-house integrated digital campaign spotlighting the resilience and triumphs of actual cancer fighters and survivors. This initiative was designed to uplift and empower cancer patients and their families, offering inspiration and support to navigate the physical and emotional challenges of the disease.



The campaign launch was followed by expert talks, and advertorials in leading digital publications of India which helped spread our message to diverse audiences across the country. The campaign page urged people to take up a pledge and never give up in life. 77,000 people pledged their commitment on the website to keep fighting and keep winning in life.

This year, we also launched the Lung Star Show in partnership with Bollywood celebrities like Sonu Sood and Boman Irani to raise awareness about Pneumococcal diseases across social media channels. The campaign reached more than 12 million people and helped engage 3500 healthcare professionals.



### Committed to communities in India:

In 2023, our CSR initiatives prioritized advancing new healthcare technology and enhancing access to quality healthcare information and support for patients in India. Our INDovation program continued to advance Indian startups on their journey to build scalable products that could transform the healthcare industry in our country. Collaborating with Tata Trust, our Cancer Care program deployed across 5 states – Assam, Jharkhand, Odisha, Maharashtra, and Telangana, impacted over 550,000 beneficiaries through community outreach, including organizing screenings for non-communicable diseases and providing psycho-social and financial counseling. Under Project Aastha, we established helpdesks in 14 hospitals across 12 states, aiding patients with non-medical guidance. This initiative facilitated over 100,000 patient registrations, with 58,000 instances of financial support through government schemes and 45,000 counseling sessions organized for patients. This program indirectly benefitted 250,000 beneficiaries. To touch the lives of more patients across other therapy areas, we inaugurated a Rare Disease helpdesk at the Maulana Azad Medical College in New Delhi, emphasizing our commitment to patient-centric care and unwavering belief in bringing more breakthroughs that change patients' lives.

### Startups supported by INDovation:



### Project Aastha Helpdesks:



**CSR: Pfizer's Cancer Care Programs Benefit Over 6,00,000 People In India**

More than 90,000 patients have been screened so far through a collaboration with Tata Trusts cancer care program (a Pfizer Limited initiative).

by INDIA CSR | February 7, 2023





## Sustainable solutions for stronger communities

As the world's largest biotech company, Roche has always taken its role as torchbearer in the medical world very seriously. Our scores of breakthrough treatments and our strong position as a leader in oncology, immunology, infectious diseases, and diseases of the CNS in the last 125 years are perfect proof of that. But we also take our commitment to the community just as fervently.

In India, we have frequently collaborated with the government on various programs that have had far-reaching social impact. We believe that driving the country towards a stronger, healthier future begins by building better communities. Recently, Roche along with The Centre for Environment Education Society (CEE) and Crown Agents India joined forces with Haridwar Nagar Nigam to implement Project SWACHH: Sustainable Waste Management and Community Health Initiative in Haridwar.

### SMA Warriors: Every day is a milestone!

Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disorder characterised by progressive muscle weakness and atrophy, due to the loss of motor neurons in the spinal cord. Though not very common, a recent study estimates that approximately about one in every 3,200 babies is born with this condition annually in India.

For a child suffering from SMA, every task can seem onerous, however simple. In fact, most normal tasks seem unthinkable for these children, who spend their lives on crutches or wheelchairs, struggling to make even the smallest movement.

Every year, August is observed as SMA Awareness Month as a global effort to shine the spotlight on this rare neuromuscular disease and to mobilize support for the entire SMA community. At Roche, we have left no stone unturned in our efforts to improving the lives of these patients. We believe that no patient should live without a viable treatment option, no matter how rare a disease may be. With this conviction, we launched Evrysdi, India's first and only approved oral therapy for SMA in July 2021.

Last August, SMA Awareness Month saw us launch a deeply emotional and exceptionally real effort as a salute to these brave children - the SMA warriors. This multi-stakeholder initiative was called 'Every day is a milestone' and captured stories of hope and triumph from actual patients on Evrysdi therapy who have achieved small yet significant milestones. Like holding a glass of water, turning without support or kicking a football for the very first time! It was our commitment to taking their stories further; making them heard by those who matter – HCPs, policy makers, media and PAGs. Truly, 'Every day is a milestone' acknowledged and appreciated the strife of these patients, saluting their spirit by giving them their due respect.

The heart-warming three-fold campaign used a set of 3 key visuals that highlighted the stories of 3 children living with SMA. It detailed their achievements and applauded their grit. Another part of the campaign centred around a series of letters written over a period of 10 to 15 months by patients, addressed to their treating doctors. These letters not only chronicled life updates from each child, showing steady improvements in their condition, but through the series, one could see a marked improvement in their handwriting too. Lastly, an animation film was created that depicted the role of Evrysdi through a lovable superhero named "Captain Evrysdi".

The campaign resonated positively with patients, caregivers, and other stakeholders. It helped create awareness about the disease. And spread hope about possible interventions.



### Pioneering an immersive experience: Perfecting patient outcomes.

August marked another major milestone for Roche. On the 24th of the month, we established the first-ever Roche Experience Center in Chennai, India. Using state-of-the-art technology, it aims to revolutionize the approach to healthcare in the country, acting as a touchpoint to boost collaborations between HCPs, researchers and educational institutions, thereby prompting better patient outcomes.

The hub uses highly sophisticated Fourth Industrial Revolution (4IR) digital technologies such as Augmented Reality (AR), Virtual Reality (VR) and Artificial Intelligence (AI), to create an immersive, interactive experience for visitors, giving them comprehensive insights into medical science, helping them visualize disease pathways and understand drug action in the human body while sharing latest information about Roche's innovative, life-changing product portfolio and technologies. It comes as the culmination of enormous efforts between Roche Global and the India affiliate. Roche Pharma India is

particularly thankful to Richard Wright (Global Head of Customer Experience and Insights), Dr. Marco Giannitrapani (Global Head for Advanced Analytics for Business Insights) and Karthik Chidambaram (Global Head of Data Assets Management) from Global Product Services (GPS), for the immeasurable project guidance, technology and content support received.

The inaugural ceremony saw many dignitaries attending, including members Government of Tamil Nadu members, representatives from renowned universities, and senior leadership from Roche, viz. Adriano Treve - CEETRIS Area Head, Richard Wright and Karthik Chidambaram. Speaking at the launch, V Simpson Emmanuel (Country GM - Roche Pharma India) called the centre the “first big step” in what is certain to become a game changer in the pharma industry. The launch received wide coverage by the media, attesting to this fact, too!

The Roche Experience Center will continue to push the boundaries of technology and customer engagement. The stand-out feature of the place is “The Wall”. Currently in a static view mode, The Wall will eventually evolve into a dynamic and then finally predictive mode. Another noteworthy aspect is the tapping of Tamil Nadu’s universities’ talent pool. Roche has tied up with four reputed tech schools & universities in the state. These partnerships will help in co-creating programs that foster development on niche skills for immersive technologies and high-end data analytics among students in these four colleges. Select students will also be provided long-term internship opportunities with Roche on immersive media, real time engines, high end data analytics and artificial intelligence.



### SWACHH: A clean mission and a green tomorrow.

After the success of the Swachh Bharat Mission's first phase, with the country being declared Open Defecation Free in 2019, the government initiated its phase two, 'ODF-Plus'. Apart from sustaining ODF behaviours, SBM 2.0 focuses on interventions for the safe management of solid and liquid waste in rural and urban areas, through the application of treatment measures that are automated processes, rather than conventional manual ones that are presently in use. Haridwar was selected for the pilot project of this program, as this pilgrim destination sees tons of organic waste being created every year.

On the 17th of May 2023, Mr. Pushkar Singh Dhama, Uttarakhand's Chief Minister, laid the foundation of the

project. The primary objective of SWACHH is the facilitation of separation of organic (wet) waste from dry waste for subsequent collection and conversion into compost, towards which up to 240 bio-composters will be installed across Haridwar. Complementing this effort, a widespread Information, Education, and Communication (IEC) campaign will also be conducted to raise awareness about the impact of Solid Waste Management (SWM) on public health.

Within a short span of six months, the project has made tremendous progress. 170 composters have been installed. Around 15 tonnes of organic waste have been diverted from landfills and are being used to make compost. As many as 105 bio-composters have already been delivered and distributed to Bulk Waste Generators (BWGs) like Ashrams, highway *dhabas*, and big residential colonies. To encourage accountability, the program is ensuring that BWGs sign commitment letters - for maintenance and regular use of bio-composters. This will keep them committed, as well as contribute to reducing the total waste going to landfill areas, with waste segregation happening at source. What's more, the manure produced through composting has created livelihood opportunities for BWGs and caretakers, with its potential for being resold. Similarly, the leachate is being diluted and used as a soil conditioner/pesticide for plants.

The project has received good coverage in the local media. Awareness drives, rallies, community gatherings, *nukkad nataks* etc, have further kept the momentum going.

SWACHH has so far delivered approx 10 tonnes of organic waste already, thereby reducing landfill waste and emissions, creating a positive impact on the environment. Plus the added benefit of soil enrichment and water conservation, as well as increased income generation opportunities. The aim of the project is to compost at least 80% of the organic waste generated by BWGs through SWACHH project in the next 3 years.



## Serving communities through Science

Sanofi is an innovative global healthcare company with a presence in 90 countries and one purpose: to chase the miracles of science to improve people's lives. The Company is discovering, developing, and delivering medicines and vaccines for millions of people around the world, and is on course to transform the practice of medicine through breakthrough science, and to make a positive impact on the people and communities we serve.

Over the last nearly 70 years, Sanofi's wide range of high-quality products in preventive healthcare (vaccines) as well as in treatment for allergy, pain, diabetes, rare diseases, and other therapeutic areas have contributed to improving the lives of people in India.

The company's social impact projects are serving India's underserved population in the area of diabetes (Type I and II) and NCDs. Sanofi has been proudly 'Making in India' since 1960. Almost 95% of Sanofi's domestic requirements are met through indigenous products. Read on about how Sanofi's 'India for India' growth plan is truly 'Bharat ke liye'.

### INDIA FOR INDIA

In 2023, Sanofi gave fresh impetus to its business in the country with an accelerated 'India for India' growth plan. This renewed strategy is focused on increasing access, intensifying innovation and improving collaboration. Thus, we aim to create ways of maximizing access to Sanofi's existing established portfolio in India, which includes our leading brands like Lantus®, Toujeo™, Amaryl®, Thymoglobuline®, Clexane®, Targocid®, Hexaxim®, Menactra®, Allegra®, Enterogermina®, Combiflam® and Cerezyme®.

Further, we are intent on fast-tracking a robust product pipeline by bringing our best-in-class and first-in-class innovations into India. We launched two products -

**Sanoxaban™ (Apixaban):** A leap in Thrombosis Management, Sanoxaban addresses stroke and embolism prevention in Non-Valvular Atrial Fibrillation (NVAF) and Venous Thromboembolism (VTE).



Sanofi 2023 - New Product launch

**Carmada™ (Sacubitril + Valsartan):** Targeting heart failure, Carmada relaxes blood vessels, lowers blood pressure, and improves heart function. With heart failure affecting 22.7 million in India, Carmada™ represents hope for improved outcomes.

In 2024 we plan to launch two mega products – Soliqua® (our advanced diabetes drug for the premix segment) and Dupixent® (the first biologic medicine for the treatment of moderate-to-severe atopic dermatitis in adults). Last year, we set up a full-fledged Trade Organization in India with the objective of engaging and collaborating with our partners, including distributors, retail chains, hospitals, and institutions. Sanofi is combining product innovation, supply localisation and strategic partnerships, along with a digital thrust to overhaul our momentum for better patient and doctor experience.

### SANOFI GLOBAL HUB (HYDERABAD)

Sanofi's Global Hub (in Hyderabad) is building a workforce for the future. The Hub is associated with multi-disciplinary expertise that is delivering services to the Medical, Commercial, Financial and R&D functions within the Company, globally, leveraging India's talent for the world.



Sanofi CSR - KIDS Sakhar Free Shukrawar - Goa



Sanofi CSR - Cervical Cancer Awareness - Howrah



Sanofi CSR - Mobile Medical Vans - Maharashtra

## SOCIAL IMPACT INITIATIVES IN INDIA

Sanofi India's social impact strategy aims to build a healthier, more resilient country by ensuring access to quality healthcare for India's underserved population. Sanofi India is committed to improving access to prevention, care, and treatment of Non-communicable Diseases (NCDs).

By leveraging our core competencies and resources, Sanofi India is building capacity and capability of sustainable healthcare systems to empower communities to lead better quality lives.

Sanofi has implemented a detailed CSR Policy which covers:

### a) Access to healthcare, capacity building and disease awareness in –

**Rare diseases:** Sanofi's global humanitarian program is an outstanding example of our relentless pursuit to provide transformative therapies to people, who have a demonstrated need, meet the program's criteria, and otherwise would not have access to such treatments. The first & longest-running program of its kind for people with lysosomal storage disorders; the program has benefitted patients in over 100 countries, and over 150 new patients are approved annually.

Patients from India first started receiving therapy under the humanitarian program in 1999, and in 2007, we started the India Charitable Access Program (INCAP) through which we started providing free

treatment to people in India afflicted with the following Lysosomal Storage Disorders (LSDs) – Gaucher, Pompe, Fabry and MPS Type I. In 2022, when the first and only therapy for ASMD was launched globally, people in India started receiving the therapy under our humanitarian program. India was one of the earliest countries to participate in the Rare Humanitarian Program, and over the last 25 years, 300+ people have received treatment under our humanitarian program in India.

**Diabetes:** We are running three social impact projects for diabetes and type 1 diabetes. Program 1 for Type 1 diabetes is creating a universal standard-of-care for the diagnosis and management of this autoimmune chronic condition, generally impacting the paediatric population and young adults. It also provides funding for free insulin, syringes, lancets, and glucose strips to 1,400 underprivileged children living with this condition.

Program 2 is a Public Private Partnership with Goa State. For this social impact collaboration, Sanofi India's team of medical experts and local leading diabetologists have been educating and upskilling the State department's healthcare personnel serving the Rashtriya Bal Swasthya Karyakram (RBSK) cell; and the Medical Officers of the Health and Wellness centers. Till date, 1670 teachers and principals, and 150,000 children across 470 schools in Goa have been sensitized about diabetes - its prevalence and better management, as well as the benefits of healthy living. Alongside, the Directorate of Health Services also partners Sanofi India to run its international programme KIDS (Kids and Diabetes in School), to raise awareness about Type 1 diabetes amongst school children.

Program 3 is a partnership with Piramal Swasthya Foundation wherein 21 mobile medical units (MMUs) are being operated across 10 districts of Maharashtra to create awareness and conduct screenings for NCDs, especially, diabetes. This project helps members of the community benefit from timely referrals at the nearest government health center.

**Cancer:** Sanofi India with its NGO partner, Indian Cancer Society is creating awareness on oral and cervical cancers in West Bengal and Telangana. In 2023, 360,000 people were reached through community sessions and 25 million through media awareness.

### b) Volunteering:

Sanofi's employees contribute their time and effort for the development of the communities. In 2023, ~1000 Sanofi employees in India across 50 locations gave ~3800 hours towards volunteering activities under four main categories: Health, Education, Environment and Capacity Building.



Sanofi Volunteering - KIDS program in schools - Mumbai



Sanofi Volunteering - Restoring natural habitat - Goa

## Placing patients at the heart of our innovation

Servier was established with a simple mission: to serve health. Thus, this global pharmaceutical group, governed by a non-profit Foundation, has always aspired to have a meaningful social impact, both for patients and for a sustainable world. With our unique governance model, we can fully serve this vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,400 employees of the Group are committed to this shared calling, a source of inspiration every day.

### Strength. Service. Sustainability.

Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries. Servier has been operating in India since 1986, developing and manufacturing all its medicines with high quality standards through CMOs.

As a world leader in cardiology and with 100 million patients treated each day worldwide, Servier's ambition is to become a renowned, focused, and innovative player in oncology by targeting difficult and hard-to-treat cancers. Thus, the group allocates over 70% of its R&D budget to Oncology. The recent opening of our future Research & Development Institute in Paris-Saclay, France, is at the heart of one of the world's strongest ecosystems in the field of scientific and technological innovation. Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. And, as always, the Group includes the patient voice at each stage of the life cycle of a medicine.

### CSR initiatives: Clear, concise, community-driven.

Creating a positive ESG impact through our CSR initiatives remains the guiding force for all our actions. During the last few years, we have been supporting various causes focusing on education and healthcare of children, women, and transgenders, through organisations like Reality Gives, GIFT, CWF, Child Help Foundation, St. Joseph's Leprosy and Quest.

## CANKIDS

Since 2023, we are supporting CanKids, a national NGO working across the entire spectrum of Childhood Cancer Care. CanKids enables better standards of treatment, care, and support for children with cancer & their families by partnering with Cancer centers and filling gaps through funding support, providing social support staff, enhancing capacities, and driving quality care. We encourage our employees to engage in activities with CanKids and children with Cancer.



Christmas celebrations with CanKids 25 Dec 2023 - Sion Hospital

## #STRIDE

While we have been supporting the transgender community through CWF, one remarkable initiative underscoring our commitment towards this cause has been our **#STRIDE** with Pride initiative aiming to meet their daily essential needs while also raising awareness about prevalent health issues. In June 2023, a group of 22 Servier India employees volunteered to engage with the transgender community in the slum area of Mahim, Mumbai, and **distributed grocery kits**. Along with our medical doctors, we conducted a **health screening for around 80 beneficiaries**. This initiative has been awarded by the Indo- French Chamber of Commerce & Industry (IFCCI) as the **Best Employee Engagement Program**.



IFCCI CSR Award 2023



## Social Responsibility

Servier India produces Hesperidin in India, an intermediary API of one of our medicines, creating a **strong social and environmental impact**. Indeed, Hesperidin extraction involves 10,000 farmers, particularly small ones, cultivating **12,000 trees** for small oranges, reducing the carbon footprint and empowering **3,000 women engaged in cultivation, sorting, and extraction**. The initiative supports **4,000 children from farmer families**, emphasizing healthcare and nourishment.



*SERVIER is committed to making a positive impact on the lives of individuals, patients and communities, striving to create a sustainable and inclusive world for all.*



## A promising partnership to promote healthcare innovation

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company, we are guided by our commitment to patients, our people and the planet.

### Fostering the future.

In December 2023, Takeda announced the signing of a three-year MoU with the Biotechnology Industry Research Assistance Council (BIRAC), a public sector enterprise set up by the Department of Biotechnology, Government of India. The MoU was announced in the presence of Dr. Jitendra Singh, Hon'ble Union Minister of State for Science & Technology, Minister of State for the Prime Minister Office, Government of India, and senior government and industry leaders.

The partnership will allow Takeda to extend advisory and mentoring support to innovators and entrepreneurs, assisting them from ideation to market deployment of new-age healthcare solutions.

Speaking of the collaboration, Sanjay Patel, Global Head of Data Digital and Technology Innovation Capability Solutions, Takeda Pharmaceuticals International AG, said, "India is a vibrant and promising healthcare market. The country's healthcare segment offers an incredible opportunity both for innovation and growth. The entrepreneurial spirit of domestic healthcare startups has the power to drive healthcare advancements not only in India but globally. This partnership between Takeda and BIRAC, thus, moves beyond convention, signifying a promise to further healthcare in a manner that sets the stage for lasting improvements in the years to come."

Serina Fischer, General Manager, Takeda Biopharmaceuticals India Pvt. Ltd. said, "At Takeda, we are committed to meeting the unmet needs of patients by discovering and delivering life-transforming treatments and innovative solutions. Our vision and mission align with the Indian Government's aspiration for local solutions to global healthcare challenges. This partnership serves as a practical blueprint, highlighting how public and private players can join forces to propel substantial and enduring advances in healthcare."

Ruchi Sogarwal, Head of Corporate Affairs, Takeda Biopharmaceuticals India Pvt. Ltd., added, "Collaborations between the government, academia and industry contribute immensely to accelerating innovation and building disruptive healthcare technology solutions for addressing unmet patient needs. Our partnership with BIRAC will allow us to foster innovations, nurturing capabilities and enhancing global competitiveness translating bioscience into bioeconomy."

The partnership was announced at the Global Bio-India (GBI) 2023 event organized by the Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India and its Public Sector Undertaking, BIRAC. GBI is a mega international congregation of biotechnology stakeholders, including international bodies, regulatory bodies, Central and State Ministries, SMEs, large industries, bioclusters, research institutes, investors, and the startup ecosystem.



## Creating a better tomorrow for the community today

Founded in Mumbai in 1961, ACG soon rose to become the world's largest integrated supplier and service provider to the pharmaceutical and nutraceutical industry. Today, the company provides solutions for almost every aspect of solid dosage manufacturing – from providing capsules, to manufacturing machinery and equipment, to protective packaging materials, to traceability solutions, successfully serving 138 countries worldwide. Yet, we are firmly rooted in our service to society– and consider community development an integral part of our being.

### Innovation and Inclusivity. Our two tenets.

At ACG, we strongly believe every company has a vital role to play in making the world a better place. From our very inception, we have taken our social responsibility very seriously. Both at work, and within the community. Way back in 1979, when we received the President's Award for employing differently abled people, we were already laying the foundation for this ethos.

Almost a decade ago, we established the ACG Cares Foundation (ACF) to implement and centralise our CSR activities. ACF's vision is to enable and support local communities with initiatives and interventions that focus on education, environment, and community health. This is done through coordination and collaboration among all stakeholders.

### Caring, Collaborative, Progressive. And Proactive.

ACF has been proactive in understanding the key developmental challenges communities are facing, and strives to improve them. We follow an integrated development approach, working with communities close by and have based it on fully 'on-boarding' community-based institutions, ensuring capability enhancement, and transferring ownership of such initiatives for the longer term.

## Environmental Impact

ACG has many ongoing programmes that benefit the environment in Dahanu and Shirwal, in Maharashtra. Most are long term, and aim to train and upskill farmers, improve environmental sustainability through better conservation practices and provide livelihood avenues to the migrating community.

### Farm Based Livelihood - Dahanu

This five-year project will benefit 600 families from 6 villages in the area. Covering 600 acres of land spread over 50 hamlets, ACF has enabled the plantation of 96,000 plants, vegetables, and trees, thereby converting 240ha of uncultivable land into productive land. Water resource development in the area has created this change, enabling harvesting of over 8mn litres, and improving agriculture and generating farm-based livelihood opportunities as well.





## Watershed Management Project - Shirwal

Conducted in 5 villages in Satara district, this laudable project has been engaging the community to adopt water conservation methods and recharge structures. It covers an area of over 915ha, and aims to promote climate resilient farming practices. By training farmers in the area, we have ensured better agriculture-based livelihood practices, and through watershed management we have helped make the land green, recharging 10mn litres of water as well!



## Climate Change Adaptation - Shirwal

By promoting soil health management and better horticulture plantation practices, through the use of renewable energy and prudent water use, we have trained the local community and benefitted 641 families from 5 villages near Shirwal. The project has also encouraged afforestation efforts in the area.

## Decentralized Waste Management - Shirwal

A project with the ultimate goal of reducing global climate change, that began almost a decade ago. Starting in 2016, ACF engaged with 6 villages over a 3-year period each, touching 1440 families in all. Community members were provided composter planter and worms, and training for converting household organic waste into compost, which was then used on domestic cultivation. Post the intervention, Gram panchayats were onboarded to sustain the project post two-years of successful execution.

The project has treated 260mt of organic waste, generating over 26.2mt of organic compost already, thereby sequestering 150mt of CO<sub>2</sub>e successfully!



## Healthy Effect

Aware that good health is one of the pillars of a strong society, the company has focused a large number of its ACF activities on promoting this. Once again, these initiatives were planned within proximity to our existing plants, thereby ensuring easier supervision and greater involvement from the teams.

### Better Health Initiative - Dahanu, Shirwal, Talegaon

These projects focused on three key areas of health – preventive, curative and collaborative, and conducted many programmes under these categories.

If prevention is better than cure, then the way to secure this, is through awareness and action! Sensitizing villagers through Health Awareness Camps that were attended by more than 7.6k people, we took it further by also conducting door to door counselling, reaching 4.2k more. These camps also achieved the target of strengthening of VHSCs (village health and sanitation committees), as they play a large part in promoting preventive measures.

Working towards community health, ACFs Mobile Health Unit treated over 24,000 people in several villages on a roster basis. This is a continuation of our earlier programme, and includes visits from a female doctor once a month. This saw a 9% increase in female patients from the previous year, making up 59% of the total patients. The Unit has diagnostic facilities, and thus, it also screened villagers periodically for NCDs, and advised them to get secondary care, if or when needed.

This referral to secondary care hospitals and the collaboration with PHC/CHC/District hospital for medicine/specialized care support was done through the formation of Village Facilitation Centres in Dahanu & Shirwal. It has benefited ~ 3500 villagers who were able to get the correct treatment at the right time, thanks to our initiative.



## Educational Impetus

Another long-term goal of the company has been to bring about change through better education. And when this mission is merged with enabling the girl child towards academics, it motivates us further!

### Better Learning Initiative (BLI)

BLI aims to improve the academic performance of girls from 8th-10th std subjects, with a focus on Maths, English and Science. The project selected schools from 15 villages, where not only were parents sensitized on the importance of educating the girl child, but teachers identified slow learners and conducted remedial education sessions with them, too. This was an onboarding project, with quarterly progress evaluations and a total of 1284 students benefitted from it. This program was honoured with Maharashtra CSR Award, held recently.





### Skill Development Project: Dahanu, Shirwal, Talegaon

In order to upskill the youth, and train them with a view to securing their livelihoods, ACF conducted 15 training programmes, successfully training 1000 men and women, who will soon be given placements. In recognition of our efforts, we were presented with a Special Commendation Award for Skill Development (Shirwal), at The CSR Journal Awards.

A large number of employees are also engaged in some of these, as well as our other existing projects, volunteering in many plantation drives and watershed projects, amongst others. Some even volunteer as teachers, too, affirming our commitment to creating better communities.



## ACG Becomes the World's First Capsule Manufacturing Factory to Join the Global Lighthouse Network Community 2023-24

- ACG Capsules Pithampur, India is ACG's 1st lighthouse to join the community
- Karan Singh, Managing Director and Balajikasiram Sundararajan, Chief Digital Officer attend the Global Light House Network ceremony in Davos to collect the award.

ACG, the world's largest integrated supplier and service provider to pharmaceutical industry celebrated the inclusion of its capsule manufacturing facility in Pithampur, India, into the esteemed Global Lighthouse Network (GLN) by the World Economic Forum at the 54th Annual Davos Summit.

The World Economic Forum's Global Lighthouse Network has acknowledged the exemplary integration of Fourth Industrial Revolution (4IR) technologies, including artificial intelligence and big data analytics, by select factories globally. These facilities have been distinguished for their commitment to enhancing efficiency, fostering sustainable development, and simultaneously advancing their workforce's skills and safeguarding the environment.

Upon receiving the award, Mr. Karan Singh, Managing Director, said: "I am delighted to receive this recognition on behalf of my team. For me the most unforgettable part of our journey wasn't any technology or efficiency milestone, but the incredible team that made it all possible. Just ordinary people, united towards one goal, bringing about innovative collaborations to push boundaries of what is possible." He added: "One of the stand-out features of our application was the Gen-AI integration. Something that was done in the less than two weeks. In between all the debate on what Gen-AI can do to humans it is a beautiful reminder that 'technology is brilliant, but humans drive the change'. Let's remember that!"

ACG operates across 138 countries in six continents and has positioned itself as a leader in the pharmaceutical sector by focusing on high-quality capsule production, increasing responsiveness, improving production yields, and boosting workforce efficiency. The company produces billions of capsules annually and has implemented over 25 innovative applications of 4IR technologies, including the industrial internet of things (IIoT), machine learning (ML), deep learning (DL), digital twins, extended reality, and generative AI.

Selwyn Noronha, CEO, ACG Capsules, added: "We are extremely proud of our first factory lighthouse. From its inception the facility has pioneered in its field, but this latest honour recognises the excellence in adopting AI at speed and scale.

"Our continued future-focused approach sets new benchmarks in quality and innovation, with the aim of ensuring maximum benefit for customers, regulators and the entire pharmaceutical ecosystem."

### About Global Lighthouse Network

Global Lighthouse Network is a collaborative platform bringing together forward-thinking manufacturers leading the charge in adopting Fourth Industrial Revolution technologies. Leveraging innovations like artificial intelligence, 3D-printing, and big data analytics, Lighthouses drive efficiency, competitiveness, and transformative business models at scale, fostering economic growth while championing workforce

augmentation, environmental protection and providing a collaborative learning journey for all-sized manufacturers globally. The Global Lighthouse Network is a World Economic Forum initiative co-founded with McKinsey & Company and counselled by an Advisory Board of industry leaders, including Contemporary Amperex Technology (CATL), Foxconn Industrial Internet, Henkel, Johnson & Johnson, Koç Holdings, Schneider Electric, and Siemens. Factories and value chains that join the network are designated by an independent panel of experts.

### About ACG

For over 60 plus years, ACG has been innovating the production solutions for pharmaceutical and nutraceutical companies, that help make people better. As the world's most integrated provider of oral dosage products and services, we produce capsules, barrier packaging materials, manufacturing machinery, and visual inspection and traceability solutions. All fully compliant with international standards. Today, ACG fosters long-term collaborative partnerships with customers in 138 countries across six continents. Together, we share a common purpose: to solve the world's greatest health challenges and make it better for everybody we serve.

*For more information, please contact the ACG media relations team:  
madhurima.chakraborty@acg-world.com*





## Delivering with Care for Planet & People

Connecting people and improving lives. This common purpose unites everything we do at DHL Group. It drives our commitment to sustainability and leverages the strengths of our team to create a lasting impact in our communities. Sustainability refers to our responsibility towards the three areas – Environment to run clean operations, Social to be a great company to work for all, and Governance to be a highly trusted company. All in all, our CO<sub>2</sub> emissions and CSR efforts are just as relevant as our EBIT or cash flow, and this is clearly represented from our on-ground efforts with DHL Supply Chain India.

### Turning Yellow into Green in India

DHL Group aims to achieve zero-emissions logistics by 2050. In addition to our commitment to the environment, we at DHL Supply Chain India adhere to clearly defined targets and measures in social responsibility and governance to be a fully compliant organization. We have successfully implemented green solutions at our warehouses such as LED Lighting (over 65,000 installed in our sites), Motion sensor systems, Solar panels, Rainwater harvesting, Waterless urinals among others to ensure minimum environmental impact from our warehousing operations. With our efforts, we have conserved over 20,000,000+ litres of water across all our sites. Our sustainable packaging solutions such as stretch wraps, biodegradable void fills and reusable cartons help ensure waste management through packaging. Through our transport operations we drive increased efficiency and the use of cleaner fuels within our fleet and with our subcontractors. We plan to have 100% usage of green fuel and electric vehicles for Intra-city distribution by 2025. To this effect, we have already started to deploy 2, 3 & 4-Wheeler Electric & Alternate fuel Vehicles for our intra-city distribution.

As the world's leading logistics company, we have a tremendous responsibility to our planet and the people we share it with. We live up to this responsibility with our GoGreen climate protection program. The GoGreen program has main areas of action: on the one hand, it includes activities to make our operations cleaner on the other hand, we want to



inspire our employees to act in a more environmentally friendly way and engage them in our climate protection activities, mainly through our Certified GoGreen Specialist training program.

### Enabling Excellence in Supply Chain for Life Sciences & Healthcare

Apart from our efforts to reduce carbon emissions and protect the planet; we take great pride in striving towards improving people's lives to have a lasting impact on our society. During the COVID 19 pandemic, just a year after the DHL group helped deliver the first vaccine, we had surpassed the milestone of delivering over 2 billion vaccines to more than 175 countries globally in our effort to support the ongoing fight against the pandemic.



In India, we are committed to our efforts in supporting life science & healthcare companies with our warehousing and transport solutions. We have also recently launched our Life Sciences and Healthcare centre of excellence (COE) site in Chennai to help support our efforts. The COE site is set to be a showcase of the best of our operational standards which will help us serve leading LSHC companies in India. To all our customers across sub-sectors such as Pharmaceuticals, Medical Devices, Clinical Trials, Hospitals & Health services; we offer a standardized Multi-customer warehousing solution that provides flexibility and supply chain synergies, cold chain storage & transport solutions, returnable / reusable packaging for cold chain that provides in-transit temperature adherence & is in line with our sustainability efforts.

For many of our LSHC customers, we have also enabled urgent overnight deliveries of critical equipment just in time for surgery/patient care, and potentially saving lives. One such customer of ours is a leading American medical technology company specializing in artificial heart valves and hemodynamic monitoring. They are a world leader in medical innovations for structural heart disease, as well as critical care and surgical monitoring. One night our account executive managing this customer received a call in the wee hours of the night for an urgent delivery of a Transcatheter Aortic Valve to Breach Candy Hospital in Mumbai. With the patient's life on the line our ground operations team processed the order and arranged transportation to duly deliver the heart valve 50 KM away from our warehouse in Bhiwandi to the hospital in South Mumbai within three hours from the first SOS call.

From enabling urgent delivery transportation of heart valves within city limits to transportation of critical cancer treating machine equipment from Mumbai all the way across country to Aizawl; we understand the urgency while enabling transportation of life-saving medical equipment and leave no stone unturned to ensure the integrity of the products in transit.



## Enabling healthcare organizations to be future-ready

Indegene is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech, and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. Indegene brings together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable, and omnichannel experience for patients and physicians. It's what drives Indegene's team and their purpose to enable healthcare organizations to be future-ready.

### New product/service launch | Invisage

Invisage is an AI-enabled proprietary platform to help life sciences organizations optimize their go-to-market model. It helps deliver personalized outcomes to healthcare professionals (HCPs) by leveraging data from over 2 million HCPs and more than 200 million HCP interactions.

Invisage is an integrated hybrid omnichannel platform that brings together data, AI-driven scientific modeling, and strategic insights to deploy digital campaigns and partner digital channels with a sales force to expand HCP reach and optimize interactions. In response to the ongoing challenges of access and cost inherent in the traditional sales force model, Invisage harnesses the shift in HCP eagerness to engage with life sciences companies through digital channels and makes it possible to target HCPs more effectively with the content they want, on the channels they prefer, at the times they are most available using a proven approach to drive prescribing behavior change.



"We are excited to introduce Invisage to the market and enable life sciences companies to effectively reach HCPs, powered by Indegene's AI-driven platform and our team of experts," said Nancy Phelan, Senior Vice President, Omnichannel Activation, Indegene. "Invisage paves the way for companies to seamlessly transition to and sustain a hybrid model, knowing that this modern approach can provide HCPs the personalized information they need to deliver improved patient outcomes."

Based on 4+ years of real-world data, this platform is rooted in Indegene's corporate vision of leveraging the latest technology to help companies grow their impact in an effective, efficient, and modern way. Powered by AI-driven technology and Indegene's proprietary data, pharmaceutical companies of all sizes can partner with Indegene to create and deploy optimized campaigns focused on reaching HCPs that have been targeted based on their affinity for digital channels and content. Indegene's intelligent segmenting model that continually adapts and adjusts to HCP engagement throughout a campaign ensures that each message is optimized for HCPs, resulting in the shortest pathway to prescription - thereby reducing costs and maximizing efforts.

Invisage's agile platform enables pharmaceutical companies at any stage of the commercialization life cycle, from launch to loss of exclusivity (LOE), to deploy omnichannel strategies quickly and efficiently and capitalize on their competitive advantage in the market. Together with the support of Indegene's team of industry-leading experts and deep domain expertise, Invisage makes it possible to deploy omnichannel in a faster and more effective way to optimize budget and drive revenue.

The Invisage platform will power Indegene's fully integrated omnichannel solution for better results leading to highly targeted customer experiences that result in improved brand performance.

For more information, please check out Indegene's Omnichannel Activation Solutions: [www.indegene.com/what-we-do/omnichannel-activation-solutions](http://www.indegene.com/what-we-do/omnichannel-activation-solutions)

### Enabling access to dialysis treatment

We joined hands with Bangalore Kidney Foundation to set up a new dialysis unit at Sanjeevini Cooperative Hospital, Hassan, to help bring quality dialysis care closer to those in need in and around the district.



### Nurturing engineers of tomorrow

37 Indegeons have volunteered to mentor engineering BTech students in over 15 different streams - from computer science to electrical to AI&ML, in partnership with Foundation for Excellence (FFE).



### Mentoring Indegene-FFE Scholars

Indegene's collaboration with FFE in the B.Pharm. mentorship program is set to make a difference. Our very own Swetha S is taking on the role of a mentor to guide Pavithra, a BPharm scholar in the scholarship program, while our CEO Manish Gupta has personally sponsored Pavithra.


### Cooking for a cause: Volunteering with Akshay Patra

The Akshay Patra Foundation supports the PM POSHAN (Mid-Day Meal) Programme, serving nutritious meals to government school children. On October 26th, a team of 13 volunteers, visited the kitchen in Rajajinagar, Bengaluru to help with the meal prep for the following day.



### Engaging with Indegene-FFE scholarship students

Indegene in partnership with the Foundation for Excellence (FFE), is supporting 25 bright medical students through a scholarship program. In a recent interaction, we had the opportunity to speak to some of these young minds on their educational and career journey.



### Improving access to Renal Healthcare

Indegene and Bangalore Kidney Foundation join hands to offer cost-effective dialysis services to patients in Karnataka. We sponsored three haemodialysis machines and provided financial assistance for three patients.

### Championing excellence with OCQ

Indegene's partnership with Olympic Gold Quest (OCQ) empowers athletes in their Olympic journey by providing training and recovery support. Our contributions towards Sports Science support facilitate achievements like Shaili Singh's record-breaking jump of 6.76 meters at the Indian Grand Prix, the 2nd longest jump by an Indian woman ever.



Shaili Singh in action at the Indian Grand Prix at Bengaluru on 15<sup>th</sup> April 2023



## Rewards, Recognitions and Resourcefulness

Parexel is among the world's largest clinical research organizations (CROs), helping hundreds of pharmaceutical companies and innovators to design and deliver thousands of lifesaving treatments faster and better. Leveraging the breadth of our clinical, regulatory, and therapeutic expertise, our team of more than 21,000 global professionals provide the full range of Phase I to IV clinical development services to our clients, with precision and perfection.

### Parexel India recognized with awards for gender parity and empowering women in the workplace.

In a testimony to our commitment to gender diversity and women's participation in the workplace, Parexel India was recognised with four DivHERSity awards from JobsForHer during their 2023 awards event held on March 3. The annual awards are a celebration of gender diversity in the workplace and recognize the exceptional work of companies to accelerate female participation and performance in the Indian workforce, which is one of the main goals of the platform.

**Our winning categories in this year's awards include:**

- Top 20 Companies in DivHERSity (Large Enterprises)
- Top 20 Most Innovative Practices — DivHERSity Policies
- Top 20 Most Innovative Practices — Women L&D Programs
- NEW for 2023! Top 3 Companies by Industry — Pharma/Biotech/Clinical Research

2023 marks our fourth year for being recognized for our efforts and achievements in India and we are especially proud to have been recognized with the Top 3 by Industry award for the first time.



*Parexel India recognized with awards for gender parity and empowering women in the workplace*

### Parexel India recognized as a “Great Place to Work”

Parexel is a great place to work, and a recent certification has just helped confirm it! The company earned Great Place to Work® (GPTW) Certification from the Great Place to Work® Institute, India. The globally recognized GPTW certification is considered the Gold Standard in identifying and recognizing great workplace culture, and this marks the second time in three years that Parexel India has been certified as a Great Place to Work®. The fact that the Institute conducts the survey confidentially, adds further validation to it.

In 2021, approximately 900 colleagues responded to the GPTW survey. This year, nearly 3,700 colleagues participated, resulting in an impressive 76% participation rate. The results are also impressive — on average, scores for Parexel India increased in all categories by 10 to 15 points and the overall Trust Index captured in the survey increased by nine points for a total score of 82.

These results prove that an overwhelming number of our colleagues agree that we've collectively built a work culture that we can be proud of.

“Being recognized as a GPTW-certified organization is a fantastic honor and testament to the hard work, commitment and dedication that every Parexel India colleague has for each other and, most importantly — our patients,” said Sanja Vyas EVP, Global SBU Head, Clinical Logistics & Safety Services & Managing Director, India. “We are incredibly proud to have received this honor in our journey towards building and sustaining a high-trust, high-performance culture.”

### Parexel Receives The CSR Journal Excellence Awards 2023

On the December 09, 2023, The CSR Journal celebrated the 6th edition of its Excellence Awards at the prestigious Bombay Stock Exchange (BSE), Mumbai. The awards were presented by Defence Minister of India, Shri Rajnath Singh and Maharashtra Chief Minister Shri Eknath Shinde. Bollywood superstar Aamir Khan graced the event.

Parexel International India Pvt Limited was awarded the runner-up award for our Project GendHer, in the category of Women Empowerment and Child Welfare. This achievement is a testament to the hard work, dedication, and strong commitment displayed by the company in catalysing positive change.

GendHer focuses on building gender sensitivity among students and imparting crucial knowledge on the health and sanitation of girls during menstruation. Guided by the Knowledge, Attitude, and Practice (KAP) framework, the campaign operates through three distinct pillars. It involves enhancing teachers' KAP to create a conducive atmosphere for students to discuss gender and menstruation freely, improving infrastructure related to Water, Sanitation, and Hygiene (WASH) in schools, and integrating gender sensitivity talks and menstrual hygiene management discussions into the school curriculum.



Parexel Receives The CSR Journal Excellence Awards 2023 - Surupa, Julian and Annappa



### Parexel celebrates the #PositivelyPurple movement

The Persons with Disabilities Day is celebrated on 3rd December. We at Parexel rang in the celebrations early, celebrating it in offices across India with enthusiasm, on the 1st of Dec. Indeed, inclusivity is embedded in the Parexel D&A, and we are committed to building an all-embracing workspace where people with disabilities can thrive. One of the ways we do it is by joining the #PositivelyPurple movement.



## Supply that's Safe, Secure & Sustainable

Pharmapoint was formed to serve the unmet need for supply of specialty pharmaceuticals till the last mile, especially those which require controlled temperature conditions. With its wide network, the group provides a PAN India footprint to clients, as together with our group companies IMS & ADS, we have 16 distribution branches across the country and cover 300+ cities servicing hospitals, doctors, patients, retail chains and pharmacies and currently service over 300+ cities. Our model ensures a strong and secure chain of custody through the drug distribution system.

India is a geographically diverse country with extreme climates and has a highly fragmented pharmaceutical distribution network. Every medicine changes hands many times before it reaches the patient; every transaction is an opportunity for falsified or substandard products to infiltrate the market. Cognizant of this flaw in the supply chain, Pharmapoint set about to create a stronger, safer, sustainable option.

Sustainability at Pharmapoint group is about more than just adopting environmentally responsible practices, it encompasses the entire product lifecycle till last mile and aims to ensure that medicines are accessible, affordable, and sustainable for all. Pharmaceutical Supply Chain has a carbon footprint in every phase and has the responsibility to find better practices. The Pharma Industry needs to redesign its entire value chain after fundamentally bringing down carbon emissions.

### Sustainable Pharmaceutical Packaging

"Global pharma packaging market size was valued at \$117.2 billion in 2021, and is expected to expand at a Compound Annual Growth Rate (CAGR) of 9.5 per cent from 2021 to 2030."

The global healthcare industry emits approximately two gigatons of CO<sub>2</sub> emissions annually, which by itself makes it equivalent to the world's fifth largest emitter country.

One of the reasons for this infamous ranking is the inefficiency during the transport of temperature-sensitive pharmaceuticals caused by the fact that about 70% to 90% of these temperature-sensitive medications are still transported in low-tech single-use packaging, which are essentially cardboard and Styrofoam boxes with cold bricks. Such packaging consume natural resources, create waste and are extremely inefficient in terms of weight-volume ratio, many weigh up to five times of actual product and use 3.5 times the space leading to higher consumption of freight and fuel.

The pharma industry can significantly reduce their environmental impact by adopting sustainable packaging solutions. Using recyclable, biodegradable, or reusable materials can substantially diminish the environmental impact of drug packaging.

Organizations across the world are working hard to reduce their use of harmful, non-sustainable packaging materials. More environmentally friendly alternatives are quickly replacing materials like plastic and polystyrene foam. But when it comes to cold chain packaging, the transition has been slower for several critical reasons.



Pharmapoint group set on its goal for developing indigenous sustainable packaging ,explored the most recent innovations allowing for efficient and eco-friendly cold chain shipping like Compostable Cold Chain Packaging Materials ,Phase Changing Materials and QR codes help to limit energy use and reduce the carbon emissions associated with cold chain shipping.

The packaging of medicines is just as important as the medicine itself. Preservation of drugs as well as the preservation of our planet are both as important as each other.

At Pharmapoint , we are constantly creating and developing new and innovative sustainable solutions using recyclable, biodegradable, or reusable materials, with our ISO-accredited processes and personal attention to detail, we help reduce packaging waste and make smarter choices to ensure our temperature sensitive products are effectively protected and can substantially diminish the environmental impact of drug packaging.

Pharmapoint has helped develop “ Made in India” sustainable packaging for “ last mile delivery “ which is the difficult and important leg for temperature sensitive products to ensure that the cold chain is not broken and maintained from manufacturer till hand over to end customer/consumer.

Quick Response codes on sides of the shipper packaging provide additional functionality to sustainable pharmaceutical packaging. These reduce the need for physical pamphlets or leaflets that would have typically accompanied with the pharmaceutical product. QR codes on sides of the shipper takes the end consumer/customer to a simple illustrated video/s which help explaining the advantages, sustainability, and the journey together for a better greener world.



**At Pharmapoint, we don't just deliver medicines .... we deliver an experience.**




**Felicitating Sustainability, Awarding Innovation.**

Recently, the sustainability shipper initiative of Pharmapoint group's IMS & ADS secured an award in the prestigious **Economic Times RE Pharma Awards**, held on 20th January 2024 in Mumbai. This was in the category “**Excellence in Packaging & Delivery**” and presented by **Dr. Rajeev Singh Raghuvanshi**, DCGI and Mr. Vivek Sehgal.



OPPI ORDINARY MEMBERS

OPPI AFFILIATE MEMBERS

## About OPPI

The Organisation of Pharmaceutical Producers of India (OPPI) established in 1965, represents the research-based global pharmaceutical companies in India. OPPI has been an integral part of the healthcare journey of the country. We remain committed to supporting the nation's healthcare objectives, putting patients at the core of all decision making and collaborating with all stakeholders to find sustainable solutions to realize the collective vision of Health for All.

Our member companies have been serving the country's healthcare ecosystem since pre-independence and continue to remain committed to patient safety and providing quality care in the future as well. As an association, our advocacy decisions, patient commitment and work are always keeping the country first and we embody the spirit of working for 'Bharat Ke Liye'; driven with innovation to find solutions for unmet medical needs, collaboration with government stakeholders, and co-creation with partners coming together to address the nation's healthcare challenges. We are committed to the Hon'ble Prime Minister Shri Narendra Modi-ji's clarion call of 'Jai Vigyan and Jai Anusandhan'.

## About Bharat Ke Liye

Bharat Ke Liye captures the essence of OPPI's commitment towards India, one that's backed by innovative solutions with a mission to improve the country's healthcare infrastructure. Along with our member companies, we have been a strong partner to the nation since pre-independence. With a strong Indian ethos and a deep understanding of the country's complex fabric, we have been investing in India to build a healthier and stronger country.

As we move towards India@100, we will continue to partner the with Government to advance its vision of Healthcare for All, investing in building India's capability to solve for health challenges of its people & the world at large. It's important now more than ever before to CONVERGE, COLLABORATE, and CO-CREATE with the Government and other stakeholders in India.

### We are #BharatKeliye

#### We were there

Since pre-independence, we've partnered with India to eradicate many diseases, address many epidemics, and solve health problems; together.

#### We are there

We've been collaborating for critical support during the pandemic, co-creating with the government to strengthen our healthcare ecosystem, converging our knowledge, and leveraging technology to innovate for unmet medical needs, all in an effort to improve the quality of care & access to healthcare.

#### We will be there

As we work towards India@100, we pledge to keep investing in the future of the nation, pushing boundaries of innovation, research, and development, to make every Indian healthy, prosperous, and resilient.

Partnering India on its mission to progress, amplifying our Hon'ble PM Shri Narendra Modiji's clarion call of **Jai Vigyan, Jai Anusandhan!**

## Connect with us on:



@OPPIIndia



OPPI India



Organisation of Pharmaceutical Producers of India (OPPI)



OPPI



[www.indiaoppi.com](http://www.indiaoppi.com)



[events@indiaoppi.com](mailto:events@indiaoppi.com)

Editor - **Asawari Sathaye**, Director Communications and Patient Advocacy, OPPI  
Content Coordinator - **Clara Rodricks**, Executive Assistant, OPPI

We gratefully acknowledge the support received from our members companies.

The contents of Year End Dossier are the copyright property of Organisation of Pharmaceutical Producers of India. Content may not be reproduced in any form without prior written permission.

# # भारत के लिए



Organisation of Pharmaceutical Producers of India

**Registered Office:** 1620, C Wing, One BKC, Bandra Kurla  
Complex, Bandra East, Mumbai-400051, India.

**Delhi Office:** S6, Vatika Business Centre, Thapar House, Third floor,  
Gate #1, 124, Janpath, New Delhi 110001, India.